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Abstract 
 
The Myc oncogene is the most studied transcription factor in 
biology. It plays an important role in development and cancer biology 
regulating cell cycle and apoptosis. The Myc oncogene is also implicated in a 
variety of other cellular processes such as self-renewal, differentiation and 
reprogramming in which its involvement is less understood. Despite growing 
evidence linking increase of Myc protein to stem-like phenotypes in cancer, the 
mechanism underlying Myc’s contribution to the acquisition of “stemness” at a 
molecular level it is not yet clear. 
To regulate its target genes, Myc binds to a specific sequence within DNA and 
mostly acts as a transcriptional activator. However, Myc down-regulates a 
small number of genes including PUMA and GADD45a the activity of which 
relies also upon FOXO3a transcription factor. In this study we have attempted 
i) to delineate the crosstalk between the Myc and FOXO3a pathways and ii) to 
suggest a molecular mechanism linking the increase of Myc protein and the 
consequent activation of its target genes to cell reprogramming. 
The RAT and hT-RPE cell lines expressing a 4-hydroxytamoxifen-inducible 
MycER chimera have been used to address the first task, demonstrating that 
following induction, Myc is rapidly recruited to PUMA and GADD45a. 
Furthermore, a concomitant switch in promoter occupancy from FOXO3a to 
PUMA was observed. Myc recruitment stimulates deacetylation of H3 and H4 
histones and methylation of the lysine 9 in H3 on both PUMA and GADD45a 
promoters leading to their downregulation. PUMA is a close neighbor of 
SUMO-activating enzyme 1 (SAE1) and whilst studying the regulation of 
PUMA, we observed a peak of RNA polymerase II in the second intron of the 
PUMA gene, responsible for activation of SAE1. We found that Myc activates 
SAE1 transcription via direct binding to canonical E-boxes in the vicinity of its 
transcription start site. The downregulation of PUMA and GADD45a and the 
up-regulation of SAE1 have also been seen in the heterogeneous primary 
murine mammary progenitor cells following their reprogramming into stem 
cells induced by Myc. On the contrary, when expression of Myc leads to the 
acquisition of ‘stemness’ within a homogeneous population of murine 
progenitor cells we observed up-regulation of PUMA while SAE1 was not 
affected, suggesting that in these cells the regulation of PUMA remains under 
the transcriptional control of p53. 
Taken together, our data highlight a role for Myc in cell growth via the specific 
inhibition of FOXO3a-dependent transcription of PUMA and GADD45a and 
add a new insight in the context of Myc-driven oncogenesis. In fact,we show 
that, at least during Myc-mediated reprogramming of heterogeneous primary 
murine mammary progenitor cells, Myc activates directly SAE1 transcription. 
The activation of SAE1 has been previously shown by others as necessary for 
cancerous transformation. 
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Introduction 
 
1.1 c-Myc and its physiological function 
 
The Myc proto-oncogene family (comprising c-myc, N-myc 
and L-myc) is the most exhaustively studied group of genes in biology. In its 
physiological role, Myc is widely expressed during embryogenesis and in 
tissue compartments of the adult that possess high proliferative capacity 
(Pelengaris et al. 2002). Myc promotes cell growth and proliferation while 
concomitantly also functioning to inhibit terminal differentiation of most cell 
types and to sensitize cells to apoptosis (Pelengaris et al. 2002). Myc is a basic 
helix-loop-helix zipper (bHLHZ) protein that heterodimerizes with the small 
bHLHz protein Max and binds the E-box sequence CACGTG (Eilers et al. 
2008). The binding of Myc-Max complex at the E-box region has been 
associated with gene activation, but Myc has been also implicated in the 
context of transcriptional repression (Eilers et al. 2008). Given Myc’s role in 
gene activation and repression, gene expression profiling has been employed 
widely to examine the effects of Myc overexpression in a wide range of 
biological settings.  The emerging trend from all of these studies indicates that 
Myc overexpression influences the regulation of genes that, collectively, 
comprise a broad range of biological functions (Patel et al. 2004b). The 
majority of up-regulated genes are involved in cell growth and more 
specifically, in ribosome biogenesis, protein synthesis and metabolism. While 
many growth-related genes are activated following Myc-expression, a few 
genes are down-regulated by Myc. These down-regulated genes are involved in 
cell cycle arrest, cell adhesion, and cell-cell communication. Given this ability 
to simultaneously control such contrasting cellular functions, Myc becomes a 
crucial mediator of normal development (Zindy et al. 2006) and tumorigenesis 
(Seoane et al.2002; Oskarsson et al. 2006). Therefore, when deregulated Myc 
may drive the limitless replicative potential characteristic of nearly all tumors 
(Hanahan and Weinberg 2000). Recently, the cell-cycle effects of ablating Myc 
have been investigated. Loss of Myc function in a rat fibroblast cell line shows 
greatly reduced rates of cell proliferation, accompanied by cell-cycle defects in 
G1 (Mateyak et al. 1997). The first notion that Myc influenced cell growth 
arises from the correlation between Myc and the expression of the rate-limiting 
translation initiation factors eIF4E and eIF2a, which are now considered to be 
direct Myc targets (Eilers et al. 2008). Several important studies show the 
insights into how Myc might promote cell proliferation, revealing the ability of 
Myc to activate or repress target genes that are involved in cell cycle 
progression. Indeed, Myc induces cyclin-E-CDK2 activity early in the G1 
phase of the cell cycle, highlighting the relevant role of Myc in G1-S 
progression (Steiner et al. 1995, Berns et al. 1997). Furthermore, Myc regulates 
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expression of the CCND2 gene (encoding cyclin D2) and CDK4, that are able 
to sequester the CDK inhibitor KIP1 in cyclin-D2-CDK4 complexes (Bouchard 
et al. 1999, Hermeking et al. 2000).  
 Studies supporting the idea that Myc might also exert important influences on 
the cell-cycle by repressing genes, show that the CDK inhibitors p15 and p21, 
which are involved in cell-cycle arrest, are inactivated upon interaction of the 
Myc-Max complex with the transcription factor MIZ1. This prevents the 
association of MIZ1 with its own co-activator p300, and thus p15 and p21 
cannot be transcriptionally activated (Staller et al. 2001, Herold et al. 2002). 
Another confounding factor which must be considered when studying Myc in 
different systems is that its function appears to be not only cell type specific 
but also context dependent. This was demonstrated in an elegant study by 
Lawlor et al. (2006) showing, through the expression profiling of murine 
pancreatic B-cells following acute Myc induction, a wave of gene activation 
and repression over time. While many of these Myc regulated genes are, as 
expected, involved in growth, cell cycle progression and metabolism, a 
significant subpopulation of the affected genes had not been identified 
previously as regulated by Myc in other profiling experiments. While the 
expression profiling studies provide a basis for understanding Myc’s broad 
effect on cells, which Myc targets are essential in a given cellular or biological 
context remains an open question. Indeed, the studies comparing binding with 
expression arrays show that a significant percentage of bound loci are also 
modulated at the transcriptional level when Myc abundance is altered (Zeller et 
al. 2006). However, although Myc binding is clearly coupled to transcription, 
there are a significant number of binding sites that are not directly associated 
with gene expression (Zeller et al. 2006). These sites may represent genes that 
are regulated contingently, dependent on a specific cell or developmental 
context, as previously mentioned.  
In recent years a non-transcriptional role for Myc in regulating gene function 
has emerged. Dominguez and colleagues demonstrated that Myc can bind to 
and stimulate origins of DNA replication, independent of Myc transcriptional 
function (Dominguez-Sola et al. 2007), highlighting the notion that the 
presumed non-productive Myc binding sites could be replication origins (Eilers 
et Eisenman 2008). An important recent analysis asked whether specific 
histone modifications correlate with genomic Myc binding and found that 
elevated H3-K4 and H3-K79 methylation and core histone acetylation (active 
marks) are characteristic of Myc binding sites (Guccione et al. 2006). These 
marks are associated with open chromatin and suggest that Myc finds its target 
promoters when the chromatin is primed for gene transcription (Lüscher et al. 
2011). Although Myc induction was not associated with an increase in 
H3K4me3, a modification associated with active promoters (Kouzarides et al. 
2007), the inhibitory activity of Myc on lysine demethylases (KDMs) may be 
important to maintain H3K4me3 levels (Lüscher et al. 2011).  
Furthermore, the association between Myc and the co-activator TRRAP 
(transformation/transcription domain associated protein) and their recruitment 
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to specific loci results in the preferential acetylation of histone H4 at a single 
nucleosome (Bouchard et al. 2001). This would alter chromatin structure to 
allow accessibility and binding of Myc-MAX complexes to target DNA 
sequences thereby modulating gene activation. Changes in histone acetylation 
were also observed in studies of genome wide approaches, in which Myc 
expression appeared to induce core histone acetylation at many different loci 
(Frank et al. 2001). 
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1.2 Myc-induced apoptosis 
It is now widely acknowledged that putative cancer cells must avoid apoptosis 
for tumor growth, indeed the net expansion of a clone of transformed cells is 
not only achieved by an increased proliferative index, but also decreased 
apoptotic rate. Ectopic expression of Myc in fibroblasts cultured in the absence 
of survival factors, leads to apoptosis, highlighting the possibility of Myc to 
possess apoptotic activity (Evan et al.1992). Although interpreted by some as a 
conflict of growth signals - oncogenes activate apoptosis if the proliferative 
pathway is blocked in some way - the most widely held view of oncoprotein 
induced apoptosis is that the induction of cell-cycle entry sensitizes the cell to 
apoptosis: cell-proliferative and apoptotic pathways are coupled (Pelengaris et 
al. 2002). Interestingly, stimulation of apoptosis by Myc may not always be a 
direct effect linked to cell cycling, but can also arise through indirect actions 
that culminate in DNA damage. Several publications link Myc to the 
accumulation of reactive oxygen species via E2F1-mediated inhibition of 
nuclear factor of kB, though the consequences, either apoptosis or growth 
arrest, might be crucially dependent on cell type (Tanaka et al. 2002, Vafa et 
al. 2002). The first insight into Myc’s role in apoptosis came from studies 
showing that Myc could induce the release of cytochrome c from mitochondria 
during apoptosis (Juin et al. 1998), causing the formation of apoptosome, and 
determining the caspase cascade (Pelengaris et al. 2002). Although the precise 
mechanism that is involved in Myc-mediated cytochrome release is unclear, 
Soucie et al. (2001) show that Myc is essential for activation of the 
proapoptotic BAX protein and subsequent cytochrome c release. Otherwise, 
the insulin-like growth factor 1 (IGF1) survival factor, inhibits Myc-induced 
apoptosis, in vitro, blocking cytochrome c release (Juin et al. 1998).  In this 
scenario, it is important to consider that, the balance of anti- and proapoptotic 
molecules that are present within a Myc-activated cell, determines whether it 
lives or dies. Another possible mechanism that links Myc and apoptosis is 
through its indirect activation of p53 via ARF (Zindy et al. 1998). The 
importance of ARF in Myc-induced apoptosis was underscored in transgenic 
mice that expressed Myc only in B-lymphocytes and had lost one or both Bmi1 
alleles. Given the role of Bmi1 in suppressing ARF and Ink4 a loss of 
expression therefore, inhibited Myc-induced lymphomagenesis by increasing 
Arf-dependent apoptosis (Jacobs et al. 1999). Taken together, these studies 
show that the mechanism by which Myc induces apoptosis may be dictated by 
cell type and moreover, it may be modified by the presence or absence of 
additional mutations in other pro- and anti apoptotic genes. 
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1.3 c-Myc inhibits cell differentiation 
The ability of Myc to bind to a large number of genomic loci has been also 
demonstrated in ES cells (Kim et al. 2008). Indeed, Myc is part of the “magic 
quartet” of transcription factors that can reprogram somatic cells into induced 
pluripotent stem cells (iPSCs). Several studies found that ectopic expression of 
Myc augments the ability of Oct4, Sox2 and Klf4 to induce the formation of 
pluripotent cells from mouse and human fibroblast, liver cells, and mature B 
cells (Okita et al. 2007, Takahashi et al 2007, Werning et al. 2007, Hanna et al. 
2008). Oct4 and Sox2 are required for reprogramming, but the combination of 
other reprogramming factors can be flexible. For example, another set of 
mediators (Oct4, Sox2, Lin28 and the pluripotency factor Nanog) has been 
shown to reprogram human somatic cells into iPSCs (Yu et al. 2007). The 
frequency of reprogramming of primary cells is very low even when all the 
required factors are expressed in most cells, indicating that there are barriers 
that block successful reprogramming. Overexpression of oncogenic factors 
such as Myc in somatic cells during reprogramming induce ARF/p53-
dependent pathways, leading to senescence or apoptosis (Pelengaris et al. 
2002). Therefore, p53 could be a crucial barrier to induced pluripotency. This 
idea was supported by several studies reporting a great increase in the 
reprogramming frequency of p53-deficient mouse and human fibroblasts when 
compared to their WT counterpart (Zhao et al. 2008, Kawamura et al. 2008, 
Marion et al. 2009, Utikal et al. 2009). Moreover, the elimination of ARF, a 
potent activator of p53 in response to oncogenic stress, also increases the 
reprogramming efficiency, further implicating p53 as an important barrier 
controlling reprogramming (Li et al. 2009). iPS cells generated from p53 null 
mouse fibroblasts form tumors when injected into mice suggesting effects on 
genomic integrity and offering at least one general explanation for the low 
frequency of iPS generation during reprogramming (Hong et al. 2009). In fact, 
all molecules involved in iPS have some oncogenic potential, indeed Klf4, as 
Myc, is a well known oncoprotein. Several studies have shown the oncogenic 
potential of Nanog, Oct4, Lin 28 and Sox2 (Pelengaris et al. 2002, Almstrup et 
al. 2004, Hart et al. 2005). Pasi et al. (2011) confirmed the acquisition of 
genomic alterations (deletions and amplifications) in induced stem cells during 
reprogramming using several different experimental systems. The aberrations 
reported were suggestive of oncogene-induced DNA replication stress and 
were to a significant degree dependent on c-Myc expression. Taken together, 
these data suggest an explanation for why p53 inactivation facilitates stem cell 
reprogramming. The combination of overexpression of reprogramming factors, 
such as Myc, and inactivation of p53 in human cancer cells would provide the 
necessary components for the dedifferentiation of cancer cells, which might 
become cancer stem cells. In a physiological setting, Myc is essential for 
controlling the balance between self-renewal and differentiation of many adult 
stem cell types such as hematopoietic, mammary and intestinal stem cells 
(Wilson et al, Laurenti et al. 2012). Not surprisingly, Myc is also strongly 
implicated in the malignant counterpart for almost all of these adult systems 
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(Reavie et al. 2013, Orkin et al. 2011). Numerous experiments document the 
ability of Myc to inhibit terminal differentiation of multiple cell types in 
culture and to promote tumorigenesis in vivo when expressed in differentiated 
cells. In a number of cases, the resulting tumors have been transplanted, thus 
demonstrating the presence of tumor cells that are capable of self-renewal such 
as Myc-induced lymphomas and liver tumors (Shachaf et al. 2004, Giurato et 
al. 2006). Moreover, since high levels of Myc perturb terminal differentiation 
and enhance self-renewal of some committed and differentiated cells, one 
might expect that during tumor progression Myc could promote the formation 
of cancer-initiating cells that retain developmental plasticity but differ from 
their normal stem cell counterpart. The expression of Myc in hematopoietic 
stem cells (HSCs) leads to the rapid formation of pre B-cell lymphomas if 
apoptosis is blocked by coexpression of Bcl-2. Cells derived from these 
lymphomas can be differentiated into either B-lymphocytes or macrophages in 
vitro suggesting that Myc induces the expression, in differentiated cells, of a 
gene subset that resembles the expression signatures of ES cells (Wong et al. 
2008). In differentiated cells, whether Myc activates a subset of genes closely 
resembling an ESC signature or a few factors important for maintaining adult 
stemness is not yet clear (Orkin et al. 2011). The relationship between 
neoplastic cells and normal stem cells represents currently a question of top 
interest. The apparent parallels between the pathways required by tumor and 
normal stem cells have generated great interest in unraveling the mechanisms 
that regulate stemness in physiological and malignant contexts. The self-
renewal and differentiation capacity of stem cells mirrors the high proliferative 
capacity and phenotypic plasticity of tumor cells. Recently, the identification 
of genes vital to support Myc-addicted tumors through a genome wide genetic 
screen for Myc-synthetic lethal (MySL) shRNAs in human mammary epithelial 
cells has been reported (Kessler et al. 2012, Evan et al. 2012). The most 
significant candidates identified in this study are the SAE1 and SAE2 genes 
whose products associate to form the heterodimer that is a critical component 
of the SUMO activating enzyme needed for SUMO conjugation to proteins 
(Hay et al. 2005). Most importantly, SAE depleted cells with high levels of 
Myc expression were impaired in their ability to form a correct mitotic spindle 
and consequently induced apoptosis. These results highlighted the crucial role 
of SAE1/2 gene expression in protecting cells from Myc-induced genomic 
instability. Intriguingly, SAE1 is located very close to the proapoptotic PUMA 
(p53 up-regulated modulator of apoptosis) gene on the human chromosome 19, 
with conserved synteny in mouse chromosome 7. 
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1.4 PUMA: p53 upregulated modulator of apoptosis 
 
PUMA is a critical mediator of apoptosis induced by a variety of stimuli. 
PUMA encodes a BH3 only protein that functions as a proapoptotic gene 
triggering programmed cell death as a direct activator BAX and BAK that 
mediates cytochrome c release and caspase activation. PUMA induction is 
mediated in a p53-dependent and independent manner. PUMA activation by 
DNA damage is dependent by a functional p53 and mediated by a p53-
responsive element in its promoter (Kaeser and Iggo 2002; Wang et al. 2007). 
In many tumors escaping apoptosis in which p53 is mutated, deletion or 
methylation mediated inactivation of PUMA efficiently protects against 
apoptosis induced by either DNA damage or oncogene activation (Yu et al. 
2006; Yu et al. 2001). The p53 tumor suppressor pathway limits oncogenesis 
by inducing cell cycle arrest or apoptosis. In more of half of human tumors 
these pathways are impaired due to mutation in the p53 locus and inactivation 
of PUMA in a p53 independent manner is the only choice to activate the 
apoptotic pathway (Yu et al. 2001). It is expected that tumors inactivate p53 
independent PUMA expression in order to gain cellular growth advantages. It 
is intriguing that approximately 40% of primary human Burkitt lymphomas 
(BLs), in which growth advantage is due to Myc oncogene over-expression, 
express mutant p53, and undetectable PUMA levels due to DNA 
hypermethylation and or inactive histone marks (H3K9me2) of the PUMA 
locus (Garrison et al. 2008). These finding suggest an inverse correlation of 
Myc and PUMA expression. PUMA is normally expressed at low levels and it 
is rapidly induced in response to stress signals (Yu et al. 2001). Binding sites 
for a multiple transcription factors in the PUMA regulatory regions have been 
found, and the functional role of p53, p73, Slug and FOXO3a in PUMA 
activation following stress in vivo have been investigated (Matallanas et al. 
2007; Melino et al. 2004; Ming et al. 2008). In particular, FOXO3a-dependent 
regulation of PUMA in response to cytokine and growth factor withdrawal has 
been documented (You et al. 2006). Studies performed by large-scale 
chromatin immunoprecipitation (ChIP) have identified high affinity Myc 
binding E-boxes in the regulatory regions of PUMA. Moreover, clustering Myc 
target genes on the basis of histone modification marks, the PUMA E-boxes 
are characterized by high levels of histone methylation at H3K4me3, a pre-
requisite for Myc binding and H3K9me2, which is generally considered a 
repressive mark. Since the functional relevance of Myc binding on PUMA E-
boxes has not been addressed, here we report our investigation aimed at 
defining the functional role of Myc in regulating PUMA transcription. 
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Aim 
 
Myc is overexpressed and/or activated in cancer. However, 
the full extent of the molecular mechanisms responsible for its action is not yet 
fully delineated. It is generally believed that the transcriptional rate of Myc 
targets is increased in most instances. However, despite this observation, a few 
negatively regulated targets have been identified over the years. Our laboratory 
has a long-standing interest in transcription modulation by Myc. 
Considering that an overpowering majority of studies within the Myc field 
concentrates their research on the positively regulated Myc targets, we wanted 
to gain some insight into the regulation of two of the negatively controlled 
genes: PUMA and GADD45a. In particular, we were intrigued by the fact that 
the two genes are also targets of FOXO3a. Thus, to determine the extent of 
crosstalk between the Myc and FOXO3a pathways and investigate the 
biological significance of such interactions, we embarked upon the delineation 
of a mechanism that links transcriptional regulation by Myc and FOXO3a 
through PUMA and GADD45a.  
As a serendipitous finding that we came across during this first part of the 
study, we identified a site of Pol II binding in the second intron of the PUMA 
gene. An investigation that followed showed that it was responsible for the 
transcription of PUMA’s neighbor – SAE1, a gene otherwise implicated in 
Myc-mediated oncogenesis (Kessler et al. 2012). Therefore, we have focused 
our current study on regulation of the PUMA-SAE1 locus using different 
models of Myc induction. Specifically, we have manipulated Myc expression 
in several models of cancer and during “reprogramming” of murine mammary 
progenitors to a stem-like state with the scope of providing a molecular 
explanation for the phenomenon of synthetic lethality of Myc overexpression 
and SAE1/2 silencing. 
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Materials and Methods 
 
3.1 Cell culture and drugs 
RAT1 cells and hT-RPE expressing a 4-hydroxytamoxifen (OHT)-inducible 
MycER chimera (Littlewood et al. 1995), RAT1 and RAT-Myc-/- cells were 
cultured in DMEM medium supplemented with 10% fetal calf serum. Cells 
were made quiescent by contact inhibition followed by serum removal for 2 
days. To induce entry into the cycle, synchronized growth-arrested cells were 
treated with OHT (1mM) alone or serum alone or OHT plus serum as indicated 
in the text and harvested at the indicated times. The AKT-inhibitor LY294002 
(10mM) was added in the media where indicated. Growing RAT-MycER cells 
were treated with OHT for Myc induction (Myc) for 4h. OHT-treated and 
control-untreated cells were incubated with CPT (12 mM for 4 h) or Nutlin-3 
(10 mM for 4 h) and prior to the quantification of PUMA and/or GADD45a 
mRNA levels by qPCR.  
 
3.2 Transfections and siRNA 
To carry out transient transfection experiments in RAT1 and RAT-MycER 
cells (Amente et al. 2010), we used MicroPoRATor Digital Bio Technology, a 
pipette-type electroporation. Indicated plasmids, DNAs or siRNA were 
introduced into each 3 X 106 dissociated cells in 100 ml volume according to 
manufacturer’s instructions. Pulse width was determined according to applied 
voltages: 1400 V, 30 ms, 1 pulse. Electroporated cells were then seeded into 
100-mm culture dishes containing 5 ml of culture media. After 5h of recovery, 
the cells were serum deprived for 48h. For siRNA treatments, ON-
TARGETplus SMARTpool (L-003282- 00-0005) Myc; and ON-TARGETplus 
Non-targeting pool (D-001810-10-5) were obtained from Dharmacon. An 
amount of 100nM, final concentration of the pools, was used for each 
transfection. Expression of proteins was determined by western blot. In 
transfection experiments, RAT-MycER cells were transfected with the 3mg of 
FOXO3a-TM vector expressing a constitutively active FOXO3a by 
electroporation after 5h of recovery, the cells were serum deprived for 48h and 
mRNA levels were evaluated 1 and 4h after treatment with serum and OHT. 
 
3.3 mRNA quantification by qPCR 
cDNA was prepared from total RNA with the Quantitect Reverse Transcription 
Kit (Qiagen) according to manufactory’s instructions. Each sample was 
assayed in triplicate. The qPCR data were normalized to the expression of the 
housekeeping b-glucuronidase (GUS) gene and after normalization the data 
were presented as fold change relative to the 0 point. 
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3.4 Quantitative chromatin immunoprecipitation 
Following a wash with PBS, appropriate cells were cross-linked with a 1% 
formaldehyde/PBS solution for 5 min at room temperature. Cross-linking was 
stopped by adding glycine and samples were processed using the chromatin 
immunoprecipitation (ChIP) assay kit (Upstate Biotechnology) according to 
the manufacturer’s protocol. Antibodies used in these experiments were as 
follows: c-Myc (N-262 Santa Cruz), anti-pol II monoclonal antibodies 
(8WG16, H14, H5, Covance), anti GADD45a (Santa Cruz), anti-H3K4me3, 
anti-H3K4me2, anti-H3K9me3, anti-H3K9me2 (Abcam), anti-H4Ac and H3Ac 
(Upstate). Immunoprecipitated untreated and input DNA values were used to 
subtract/normalize the values from ChIP samples. All values represent the 
average of at least three independent experiments. Untreated and input DNA 
values were used to subtract/normalize the values from qChIP samples 
according to the formula: % Input = 2DCt 3; DCt = Ct (input)- Ct( cIP). qRT–
PCR and qChIP data are presented as means of three at least independent 
experiment. 
 
3.5 Induced mammary stem cells.  
To prepare mammosphere cultures, mammary tissue from 5-month-old virgin 
female FVB mice (Harlan) were collected and dissociated mechanically. 
Disaggregation of the tissue was completed by enzymatic digestion in DMEM 
supplemented with 100 U/ml hyaluronidase (Sigma, St. Louis, MO, USA) and 
200U/ml Collagenase (Sigma) for approximately 3 h at 37°C. The digested 
material was then centrifuged and ﬁltered through 100, 70, 40 and 20uM 
meshes. Red blood cells were lysed by incubating the cell suspension in 0.2% 
NaCl. The resulting cells were plated on ultralow adhesion plates (Falcon, BD 
Biosciences, San Jose, CA, USA) at 100000 cells/ml in MEBM medium 
(BioWhittaker, Walkersville, MD, USA) supplemented with 5mg/ml insulin, 
0.5mg/ml hydrocortisone, 2% B27 (Invitrogen, Carlsbad, CA, USA), 20ng/ml 
EGF and βFGF (BD Biosciences, San Jose, CA, USA) and 4mg/ml heparin 
(Sigma). Primary mammospheres were allowed to form for 6 days. At 
passaging, the number of mammospheres was counted, the mammospheres 
were then dissociated in single cells and the number of cells counted. A total of 
5000 cells were then plated in 24-well plates. 
Clearly, the number of mammospheres at each passage reﬂects the number of 
stem cells that had been plated, the rationale being that a stem cell can form a 
mammosphere, whereas, by deﬁnition, a progenitor cell cannot do it. In order 
to distinguish native stem cells from progenitor cells, primary mammary cells 
were stained with a lipophilic PKH26 dye (Sigma) for 5min. The reaction was 
blocked in 1% BSA and the cells were plated and passaged twice to obtain 
secondary mammospheres. Single cells obtained from disaggregated secondary 
mammospheres were sorted by ﬂow cytometry on the basis of PKH26 
ﬂuorescence intensity (FACS Vantage SE ﬂow cytometer, Becton and 
Dickinson, Franklin Lakes, NJ, USA). The PKH26-high population was 
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isolated as the most epiﬂuorescent of the total population (about 1,7 % of the 
cells). PKH26-negative cells were gated at 10 times less ﬂuorescence units 
with respect to the PKH26-high population (about 70% of the cells). Since 
stem cells divide once or just a few times during each passage, they retain high 
levels of the dye, whereas the progenitor cells that divide many times, become 
PKH-negative. Lentiviral infections were performed using the PWPI vector 
(Addgene, Cambridge, MA, USA) that contains the GFP reporter gene and 
either no other insert (Empty Vector) or MycER as an insert. Disaggregated 
primary mammospheres or PKH26-negative cells were plated in Phoenix-
generated viral supernatant and infections were carried out in three cycles of 6h 
each. After 6 days of culture, secondary mammospheres were harvested, 
disaggregated and FACS sorted for the expression of GFP. For serial passage 
experiments, 5000 cells from disaggregated mammospheres were plated in 24-
well plates and, after 6 days, counted, and replated at the same density. 
Treatment with 500nM OHT (Sigma) was performed for a range of duration of 
time after mammospheres formation (0, 4, 8, 24, 30hrs). Immunoblot analysis 
of protein extracts from mammosphere cultures was performed using anti-
vinculin (Sigma), anti-phospho-serine15-p53 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), primary antibodies, HRP conjugated secondary 
antibodies (Sigma) and the SuperSignal West Pico Substrate detection kit 
(Pierce, Rockford, IL, USA).  
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Results and Discussion 
 
4.1 Myc and FOXO3a exert opposite control of PUMA transcription 
4.1.1 Myc contributes to the repression of PUMA and GADD45a expression 
following growth stimulation 
 
Since the functional relevance of Myc binding on PUMA E-boxes has not been 
addressed, here we report our investigation aimed at the definition of the 
functional role of Myc in regulating PUMA transcription. 
To this end, we employed the RAT-MycER fibroblast cell line (Gargano et al. 
2007) in which an inducible MycER protein is expressed upon treatment with 
4-hydroxytamoxifen (OHT). The expression of PUMA and GADD45a was 
monitored in asynchronous RAT-MycER cells, and in cells that were serum-
deprived for 2 days and then treated with OHT/serum. As expected, PUMA 
and GADD45a expression increased in response to growth factor deprivation, 
whilst their expression was inhibited following the serum-addition (Fig. 1A 
and 1B). In the absence of serum, the phosphoinositide 3-kinase PI3K/AKT 
pathway is inactive and FOXO3a remains unphosphorylated in the nucleus 
where it activates target genes (Accili et al. 2004, Brunet et al. 1999). 
FOXO3a phosphorylation is inhibited by serum withdrawal but it is restored 4h 
after serum addition (Fig. 1A). Moreover, the presence of PI3-K inhibitor 
LY294002 or the overexpression of the constitutively active FOXO3a-TM 
prevents PUMA and GADD45a repression by serum (Fig. 1C). Collectively, 
these data indicate that activation of FOXO3a, in serum deprived RAT-MycER 
cells, stimulates the expression of PUMA and GADD45a. On the contrary, the 
cell growth stimulation by serum is accompanied by repression of their 
FOXO3a-dependent expression. 
Utilizing the conditional expression of Myc in the RAT-MycER cells, we 
sought to determine the relative contribution of Myc to the repression of 
FOXO3a target genes. The silencing of Myc with specific siRNA restores 
PUMA and GADD45a expression to levels similar to those in serum-starved 
cells (Fig. 2A), whilst it reduces the expression of Nucleolin (NUC), a well-
defined Myc-target (Amente et al. 2010). In serum starved cells, we did not 
detect significant differences in the relative levels of mRNA in samples treated 
with specific and control siRNAs suggesting that in such cells, the expression 
of both PUMA and GADD45a is mainly independent from Myc. To determine 
the relative contribution of serum and Myc activation to the repression of 
PUMA and GADD45a, we compared the relative levels of expression in cells 
that were treated with serum alone, OHT or serum–OHT together. We found 
that Myc is able to repress FOXO3a-target genes even in the absence of serum, 
although under these conditions the kinetics of the inhibition is slower (Fig. 
2B).  
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However, serum does not fully substitute for Myc in the repression of PUMA 
and GADD45a. Indeed, the results obtained from RAT-Myc-/- cells show that 
the serum addition does not fully repress FOXO3a-targets (Fig. 2C). Moreover, 
a robust repression of PUMA and GADD45a mRNA levels were restored in 
RAT-Myc-/- transfected with Myc (Fig. 2C). To further investigate the 
endogenous Myc activity in response to serum addition, we monitored PUMA 
and GADD45a expression in RAT1 cells that were serum deprived for 2 days 
and then treated with serum for cell cycle re-entry. Upon addition of serum, the 
expression of both PUMA and GADD45a was inhibited, and most importantly 
silencing of endogenous Myc restored PUMA and GADD45a expression (Fig. 
2D). Collectively, these results highlight a crucial role of Myc in the inhibition 
of FOXO3a-dependent gene expression in response to growth factor 
stimulation.
  
Figure 1. Myc inhibits FOXO3a-depeendent transcription. Asynchronous RAT-MycER growing 
cells (Gr) were serum deprived for 2 days (0) and then treated with serum and OHT for 4 h. (A) 
Protein expression is shown in immunoblots of whole-cell extracts with anti-PUMA, anti GADD45, 
anti-Phospho-FOXO3a, anti FOXO3a and anti actin for loading control. (B) mRNA expression levels 
of PUMA and GADD45a were quantified by qRT-PCR in asynchronous RAT-MycER growing cells 
(Gr), quiescent (0) and after 1 and 4 h of treatment with serum and OHT. mRNA levels were 
normalized to b-glucuronidase (GUS) mRNA levels. All values represent the average of at least 
three independent experiments. Error bars indicate SD. (C) RAT-MycER cells were transfected with 
the FOXO3a-TM vector expressing a constitutively active FOXO3a by electroporation as described; 
after 5h of recovery, the cells were serum deprived for 48 h and mRNA levels were evaluated 1 and 
4 h after Myc induction in the presence of serum + OHT. The AKT-inhibitor LY294002 (10mM) was 
added to the media where indicated. mRNA expression was quantified by qRT–PCR and compared 
to quiescent cells. mRNA levels were normalized to b-glucuronidase (GUS) mRNA levels. All values 
represent the average +/- SD (n = 3). Error bars are standard error of the mean. *P < 0.05, **P < 
0.01. 
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Figure 2. Myc knockdown prevents repression of FOXO3a targets. (A) Serum deprived RAT-MycER 
cells (0) were treated for 4h with OHT+ serum. Myc expression was inhibited with specific siRNA (siMyc) 
and siRNA non-targeting (siCtl) was used as scrambled RNAs. PUMA, GADD45a and NUC mRNAs 
expression levels were quantified by qRT–PCR. Error bars indicate SD (n=3). Error bars are standard error 
of the mean. *P < 0.05. The efficiency of Myc silencing by siRNA treatments measured by qRT–PCR and by 
immunoblot is shown on the right. (B) Quiescent RAT-MycER cells were stimulated with OHT+serum (black 
square), with OHT alone (empty circle) or with serum alone (black triangles) and expression levels of PUMA 
and GADD45a were quantified by reverse transcription and real-time PCR at the indicated times after 
treatment; values were compared to quiescent cells and presented as means of two independent 
experiments each analyzed by triplicate qRT–PCR. (C) RAT-Myc-/- cells as well as cells transfected with a 
Myc expression vector were serum deprived for 48 h and PUMA and GADD45a mRNA levels were 
evaluated by qRT–PCR 4 h after serum induction. Values were compared to quiescent cells. (D) Serum 
deprived (2 days) RAT1 cells (0) were treated with serum (10%) for 4h. Myc expression was inhibited with 
specific siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs. PUMA and GADD45 
mRNAs expression levels were quantified by qRT–PCR. Error bars indicate +/- SD (n=3), *P<0.05. The 
efficiency of Myc silencing by siRNA treatments measured by immunoblot is shown on the bottom. 
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4.1.2 FOXO3a and Myc occupancy on PUMA and GADD45a chromatin is 
mutually exclusive 
 
Previous reports showed that Myc represses GADD45a through binding to a 
sequence proximal to the promoter (Tran et al. 2002; Barsyte-Lovejoy, 2004), 
and several high affinity E-box sites have been mapped upstream of the ATG 
site of PUMA (Guccione et al. 2006; Yu and Zhang 2008), although a direct 
proof of Myc binding to these putative E-boxes has lacked. Large scale 
chromatin immunoprecipitation (ChIP) approach showed that PUMA contains 
high affinity E-box sites, suggesting it being a putative direct target of Myc. 
Moreover, clustering Myc target genes on the basis of histone modification 
marks, the PUMA E-boxes are characterized by high levels of histone 
methylation at H3K4me3, a pre-requisite for Myc binding and at H3K9me2, 
which is generally considered a repressive mark (Cloos et al. 2008; Kouzarides 
2007). To assess Myc and FOXO3a occupancy on FOXO3a-targets (PUMA 
and GADD45) we carried out qChIP analysis in growing RAT-MycER cells 
(Gr), serum deprived for 2 days (0’) and treated for 60’ and 240’ with 
OHT/serum. Thus, we determined that the PUMA E-boxII has the highest 
affinity for Myc binding and that Myc is recruited on this site around 60’ after 
induction (Figure 3). The starvation of cells leads to recruitment of FOXO3a to 
to the fork head responsive element (FHRE) sequence and associated 
expression of PUMA (Figure. 1A, 1B and 4A). As soon as Myc is recruited 
onto the E-boxII, FOXO3a disappears from PUMA chromatin. Similar results 
were obtained by exploring GADD45a FHRE and TSS for FOXO3a and Myc 
occupancy (Figure 4B). These results indicate that upon cell cycle re-entry and 
Myc activation, there is a concomitant switch in promoter occupancy from 
FOXO3a to Myc resulting in transcriptional repression. Accordingly, we also 
determined that the Rbp1, large subunit of RNAPII, occupancy at the 
transcription start sites of both PUMA and GADD45a is sharply reduced 60’ 
after Myc activation (Figure 4C). To work out the relevance of serum on the 
reciprocal inhibition of binding to the chromatin of Myc and FOXO3a we 
performed a qChIP analysis in the RAT-Myc-/- cells of FOXO3a occupancy in 
starved and serum-induced cells. As shown in Figure 3D, FOXO3a occupancy 
of the PUMA and GADD45a FHRE chromatin after 60’ and 240’ is marginally 
affected by serum addition compared to the strong reduction of FOXO3a 
observed in the presence of Myc, pointing at a causative role of Myc in the 
repression of FOXO3a-dependent transcription. 
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Figure 3. Myc recruitment on PUMA chromatin following Myc induction.  
Myc occupancy is analyzed by qChIP in RAT-MycER serum starved cells (0’) and after Myc 
activation (OHT/serum) a the indicate times (60’ and 240’). Amplicons used for the analysis of three 
prutative E-boxes (-1000, +666, +1350) are shown below the simplified structure of the PUMA gene.  
Figure 4. Myc, FOXO3a and Rpb1 occupancy on PUMA and GADD45a chromatin. Asynchronous 
RAT-MycER growing cells (Gr) were serum deprived for 2 days (0’) and then treated with serum and 
OHT serum for Myc activation at the indicated times (30’, 60’ and 240’). qChIP was performed using 
antibodies recognizing FOXO3a (A), Myc (B) and Rpb1 (C). (D) FOXO3a occupancy on PUMA and 
GADD45a chromatin in growing (Gr) starved (0’) and serum treated (60’ and 24’0) RAT Myc-/- cells. 
ChIP-enriched DNA was quantified by real-time PCR analysis using amplicons reported in 
Supplementary Data. The values reported were calculated as fold percentage of amount of 
immunoprecipitated DNA relative to that present in total input chromatin. All qChIP data are presented 
as mean of at least three independent biological experiments each analyzed by triplicate +/- SDs. ACHR 
promoter amplicon was used as negative control in all experiments. 
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4.1.3 Myc induces H3K9 methylation and H3K4 de-acetylation on FOXO3a-
targets chromatin 
 
Myc responsive regions within the genome are characterized by specific 
histones marks (Guccione et al. 2006; Martinato et al. 2008; Zeller et al. 2006). 
High affinity Myc binding sites are marked by tri-methylation of lysine 4 in the 
histone H3 tail. Upon Myc binding, changes in the methylation and acetylation 
levels of histones H3 and H4 have been correlated to the Myc positive or 
negative effects on transcription efficiency of its targets (Cowling and Cole 
2006; Eilers and Eisenman 2008). We analyzed by ChIP histone methylation 
and acetylation marks on PUMA TSS and E-boxII sequences (Figure 5) and on 
GADD45a FHRE and TSS sequences (Figure 6) following Myc binding, 
concentrating on the methylation profile of lysine 4 and 9 of histone H3 and on 
pan-acetylation of histones H3 and H4. While H3K4me3, H3K4me2 and 
H3K9me3 levels remained largely un-changed, a robust increase of H3K9me2 
was found on PUMA TSS and E-boxII upon treatment with serum and MycER 
nuclear translocation by OHT treatment (Figure 5). Concurrent with Myc 
binding, we also detected a reduction in acetylated H3 and H4 levels on PUMA 
TSS and E-boxII sequences (Figure 5). Similar changes in chromatin 
modifications were found on the chromatin of the GADD45a gene (Figure 6). 
However, the combined treatment of RAT-MycER cells with OHT and serum 
does not allow for the discrimination between the effects of Myc activation and 
serum-induced inactivation of FOXO3a. To define the relative contribution of 
Myc activation and serum, we performed qChIP on RAT1 cells that only 
express the endogenous Myc analyzing histone modifications on GADD45a 
and PUMA chromatin in serum starved versus serum-treated cells. Comparing 
the ChIP data from RAT-MycER (Figures 5 and 6) with RAT1 cells (Figure 7 
and 8) we found, as consequence of serum addiction to starved cells, a slower 
(4h versus 1h) reduction of acetylated H3/H4 (Figure 8 panel A and B) on both 
PUMA and GADD45a chromatin (Figure 7), and increased levels of 
methylation of H3K9 (Figure 8C) in the RAT1 cells. Furthermore, to support 
the relevant role of the endogenous Myc, we silenced its expression in RAT1 
cells and, as shown in Figure 8D, found that the levels of H3 and H4 
acetylation are chiefly unaffected in silenced cells, suggesting a causative role 
of Myc in the H3/H4 acetylation reduction following serum stimulation. To 
further support the role of Myc in the loss of H3 and H4 acetylation, we have 
used RAT-Myc-/- cells to analyze AcH3/H4 presence within FOXO3a-targets. 
In this Myc null cell line, after 60’ and 240’ of serum starvation, acetylation 
levels H3/H4 of the both PUMA and GADD45a chromatin is unaffected, 
consistent with a relevant role of Myc in the reduction of H3- and H4-
acetylated levels of both PUMA and GADD45a (Figure 9A). Finally, the 
inhibition of histone deacetylases by TSA severely impairs Myc inhibitory 
effect on PUMA and GADD45a expression, following Myc induction (Figure 
9B and C). These data indicate that Myc binding on PUMA and GADD45a 
! ##!
regulatory regions correlates with increased methylation of H3K9 and with 
deacetylation of H3/H4. 
 
  
Figure 5. Histone modifications on PUMA chromatin following Myc activation. RAT-MycER serum starved 
cells (0’) are compared to cells induced with OHT and serum for Myc activation (60’). qChIP was performed 
using specific antibodies recognizing H3K4me3, H3K4me2, H3K9me3, H3K9me2, Ac-H3 and Ac-H4 as 
indicated. ChIP-enriched DNA was quantified by real-time PCR analysis using amplicons surrounding PUMA 
transcription start site (TSS) and E-BoxII. The qChIP data are presented as in Figure 4 and ChIP-enriched DNA 
was quantified as previously indicated. 
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Figure 6. Histone modifications on GADD45a chromatin following Myc activation. RAT-
MycER serum starved cells (00) are compared to cells induced with OHT and serum for Myc 
activation (60’). qChIP was performed using specific antibodies recognizing H3K4me3, H3K4me2, 
H3K9me3, H3K9me2, AcH3 and AcH4 as indicated. ChIP-enriched DNA was quantified by real-time 
PCR analysis using amplicons surrounding the TSS (-332) and FHRE (+23). The qChIP data are 
presented as described in Figure 4.
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Figure 7. Myc is required for histone modification of GADD45a chromatin. Asynchronous Rat1 
growing cells were serum deprived for two days (0’) and then treated with serum (10%) and samples 
collected at the indicated times (30’, 60’, 240’) and q ChIP was performed using specific antibodies 
recognizing H3Ac. H4Ac and H3K9me2, as indicated in panels A, B and C respectly. ChIP-enriched DNA 
was quantified by real-time PCR analysis using amplicons surrounding FHRE and TSS of GADD45a 
sequences.  
Figure 8. Myc is required for histone modification of PUMA chromatin. Asynchronous RAT1 
growing cells were serum-deprived for 2 days (0’) and then treated with serum (10%) and samples 
collected at the indicated times (30’, 60’ and 240’) and qChIP was performed using specific antibodies 
recognizing H3Ac, H4Ac and H3K9me2, as indicated in panels A, B and C. ChIP-enriched DNA was 
quantified by real-time PCR analysis using amplicons surrounding PUMA, TSS and E-BoxII. The qChIP 
data are presented as in Figure 4. (D and E) Serum deprived (2 days) RAT1 cells (0) were treated with 
serum (10%) for 4h. Myc expression was inhibited with specific siRNA (siMyc) and siRNA non-targeting 
(siCtl) was used as scrambled RNAs. qChIP was performed using antibody recognizing H4Ac, and 
ChIP-enriched DNA was quantified by real-time PCR analysis using amplicons surrounding PUMA and 
GADD45a TSS as indicated. Error bars indicate +/- SD (n = 3). The efficiency of Myc silencing by siRNA 
treatments measured by qRT–PCR is shown in (F). 
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Figure 9. Histone H4 acetylation levels at Myc targets. (A) qChIP was performed using specific antibodies recognizing 
H4Ac in RAT-Myc-/- starved cells (0’) and treated with OHT and serum at the indicated times (60’, 240’). ChIP-enriched 
DNA was quantified as previously indicated. TSA impairs Myc inhibitory effect on PUMA (B) and GADD45a (C) activated 
transcription. Serum-deprived RAT-MycER cells (0) were treated for 600 and 2400 with OHT + serum in presence or 
absence of TSA (0.2 mg/ml) as indicated. PUMA and GADD45 expression levels were quantified by qRT– PCR. Error bars 
indicate +/- SD (n=3), *P<0.01. 
!
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4.1.4 Myc does not interfere with p53 mediated activation of PUMA 
 
We sought to determine the specificity of Myc repressive effect on PUMA 
transcription independently from FOXO3a activation. PUMA expression 
following DNA damage is stimulated by p53 binding, through consensus p53-
responsive elements located within its promoter. To determine whether Myc 
may suppress p53-mediated activation of PUMA, we analyzed the effect of 
Myc in the presence of active p53. p53 is activated by the DNA damaging 
compound Camptothecin (CPT) or by Nutlin-3, which disrupting the p53-
MDM2 interaction thus releasing the active form of p53 (Vassilev et al. 2004). 
Asynchronous RAT-MycER growing cells were treated with CPT or Nutlin-3 
for 4 h prior to Myc activation and PUMA mRNA levels were quantified by 
qRT-PCR (Figure 10A). Both CPT and Nutlin-3 treatment activate PUMA 
expression in the presence or absence of Myc. Moreover, we performed qChIP 
to analyze the occupancy of Myc and Rpb1 on PUMA regulatory regions 
following p53 activation. Figure 10B shows that, in condition in which CPT 
and Nutlin-3 activate PUMA, E-box occupancy by Myc is unaffected. 
Accordingly, TSS occupancy by Rpb1 in cells with active p53 remains 
unchanged after Myc activation (Figure 10C). These data demonstrate that 
Myc binding does not interfere with p53-mediated activation of PUMA and 
indicate that Myc is not a global repressor of PUMA expression. 
 
 
 
 
 
Figure 10. Myc does not repress p53-dependent PUMA activation. (A) Growing RAT-MycER cells 
were treated with OHT for Myc induction (Myc) for 4h. OHT-treated and control-untreated cells were 
incubated with CPT (12mM for 4h) or Nutlin-3 (10mM for 4h) and then PUMA mRNA levels were 
quantified by qPCR as described in Figure 1. In parallel, recruitment of Myc (B) and Rpb1(C) on PUMA 
chromatin was determined by qChIP using the E-BoxII and TTS amplicons. All qChIP data are 
presented as mean of at least three independent biological experiments each analyzed by triplicate 
SDs, *P<0.05, **P<0.01. (D) Schematic model underlying the reciprocal role of Myc and FOXO3a in 
regulation of expression of growth promoting and growth arresting genes. 
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4.2. SUMO-activating SAE1 transcription is positively regulated by Myc 
 
Our previous results have shown that the proapoptotic PUMA gene is a Myc 
target and through recruitment to an E-box binding site on its promoter, Myc 
cooperates with the PI3/AKT pathway to repress FOXO3a mediated activation 
of PUMA expression (Amente et al. 2010). 
During that study we were intrigued by the presence of a Myc responsive 
RNAPII peak in the second intron of PUMA locus in condition in which 
PUMA expression was inhibited. This finding instigated a search of actively 
expressed genes responsive to Myc activation in the region downstream of 
PUMA resulting in the identification of SUMO-activating enzyme SAE1 gene 
whose transcription proceeds in the opposite strand to PUMA. SAE1 in 
association with SAE2 form a critical component of the SUMO-activating 
enzyme necessary for SUMO conjugation to proteins (Hay 2005).To determine 
the expression of SAE1 in the presence of hyper-activated Myc protein, we 
used the RAT-MycER and the human retinal hT-RPE-MycER cell lines in 
which the inducible Myc estrogen receptor fusion transgene is activated upon 
treatment with tamoxifen (Alfano et al. 2010; Amente et al. 2011). As shown 
in figure 11A, in RAT-MycER, SAE1 expression as well as NUC, a known 
Myc target, increases in response to Myc activation while the levels of 
expression of PUMA are inhibited. To determine the contribution of Myc to 
the SAE1 activation we silenced Myc in the RAT-MycER cells and found 
abrogation of SAE1 transcription (Figure 11B). To further determine the 
contribution of Myc to SAE1 activation, we used the isogenic RAT-Myc-/- cells 
and measured SAE1 expression levels in starved versus serum-induced cells. 
As shown in figure 11C, SAE1 expression slightly increased upon serum 
addition while the expression was significantly higher upon transfection of 
Myc into RAT-Myc-/- cells. Collectively these results suggest that SAE1 
expression is indeed regulated by Myc. In this respect we analyzed SAE1 
expression in the retinal human Myc inducible cell line hT-RPE-MycER and, 
as shown in figure 12A, Myc activation results in induction of SAE1 
expression at levels comparable to NUC. To explore the role of Myc in SAE1 
activation we scanned its genomic sequences for putative Myc binding sites. 
Several E-box were found (Figure 12B), and we focalized our attention on two 
closely associated E-box in position close to the TSS site (-170 and -101). 
Most importantly these E-boxes are located in a region with high level of 
H3K4me3, a prerequisite for Myc binding (Figure 12B) (Guccione et al. 2006, 
Martinato et al. 2008). To assess Myc occupancy on SAE1 we carried out 
qChIP on the hT-RPE-MycER cells, which were growth factors-deprived for 2 
days (0) and treated for 6 hrs with OHT for Myc activation. Chromatin 
immuonoprecipitated using an anti-Myc antibody was analyzed using 
amplicons spanning the SAE1 and NUC E-boxes and the qChIP data (Figure 
12B) showed that Myc is recruited on the E-box sites at the SAE1 promoter 
with efficiency comparable to recruitment on NUC.  
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Figure 11. Myc activates SAE1 expression. (A) mRNA expression levels of SAE1, NUC and PUMA were 
quantified by qRT –PCR in quiescent cells (0) and after 4 and 6hrs of treatment with serum and OHT. (B) 
Myc expression was inhibited with specific siRNA (siMyc) and siRNA non-targeting (siCtl) was used as 
scrambled RNAs. SAE1 mRNAs expression levels were quantified by qRT–PCR in quiescent cells (0) and 
6hrs of treatment with serum and OHT. The efficiency of Myc silencing by siRNA treatments measured by 
qRT–PCR is shown on the right. (C) RAT-Myc-/- cells as well as cells transfected with a Myc expression 
vector were serum deprived for 48 hrs. SAE1 mRNA levels were evaluated by qRT– PCR 6 hrs after serum 
induction. Values were compared to quiescent cells (0). 
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Figure 12. (A) hT-RPE-MycER cells were synchronized by 2 days of growth factors deprivation. 
SAE1, NUC and PUMA mRNAs expression levels were quantified by qRT–PCR in synchronized 
(0) and cells treated with growth factor + OHT (6hrs). All mRNA levels were normalized to !-
glucuronidase (GUS) mRNA levels and all values represent the average of at least three 
independent experiments. Error bars indicate SD. Protein expression is shown in immunoblots of 
whole-cell extracts with anti-SAE1 and actin for loading control. (B) An adapted UCSC genome 
browser view of SAE1 genomic sequence displaying H3K4me3 and H3K4me1 levels and putative 
E-box (asterisks). Myc occupancy on SAE1 and NUC chromatin in synchronized (0) and Myc 
induced hT-RPE-MycER cells for 6hrs is shown. ChIP-enriched DNA was quantified by real-time 
PCR analysis using amplicon covering the region containing the Myc binding E-boxes as shown 
in Figure 12A. 
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4.3 PUMA and SAE1: two Myc targets in mouse mammary cells  
 
In addition to the role in cancer, Myc is important for the transcriptional 
regulation in embryonic stem (ES) cells and somatic cell reprogramming. 
Indeed, Myc overexpression in adult cells can block differentiation and 
cooperates with Oct3/4, Sox2 and Klf4 in the reprogramming of adult 
differentiated cells into induced pluripotent stem cells (iPS) (Takahashi and 
Yamanaka, 2006). Myc is able to reprogram mouse mammary progenitor cells 
into mammary stem cells, as Myc expressing primary mammary cells acquire 
the ability to form mammospheres (Pasi et al. 2011). Recently, the 
identification of genes vital to support Myc-addicted tumors through a genome 
wide genetic screen for Myc-synthetic lethal (MySL) shRNAs in human 
mammary epithelial cells has been reported (Evan 2012; Kessler et al. 2012). 
SAE1 and SAE2 genes are the most significant candidates that have been 
isolated in this study (Kessler et al. 2012).  The SAE1/2 ‘s loss induces mitotic 
catastrophe and cell death upon Myc hyper-activation in cancer cells (Kessler 
et al. 2012). This latter finding (Kessler et al. 2012) prompted us to determine 
if Myc is able to regulate PUMA and SAE1 transcription also in Myc 
expressing primary murine mammary cells, and if these genes can exert a 
similar or different role in the Myc-driven cell reprogramming. To investigate 
this, we cultured primary cells from wild-type (WT) mammary tissue in non-
adherent conditions, which allow cells to proliferate in suspension as floating 
colonies (mammospheres) (Dontu et al. 2003). Their preliminary 
characterization revealed that, as reported, WT mammospheres derive from the 
clonal expansion of single cells endowed with self-renewal potential, are 
composed of epithelial cells, and are enriched in multipotent cells capable of 
differentiating along different lineages (Cicalese et al. 2009). To determine the 
expression of SAE1 and PUMA in the presence of hyper-activated Myc 
protein, we performed experiments infecting primary mammary cells with 
either lentivirus expressing MycER or its empty vector control. Control virus-
infected mammospheres prepared from wilt-type mice could be maintained 
only for a few passages in tissue culture, suggesting exhaustion of stem cell 
population. In contrast, mammospheres infected with the virus-expressing 
MycER could be easily expanded with no signs of crisis or stem cell 
exhaustion. The reprogramming of mammary progenitor cells into mammary 
stem cells was performed in the presence of 4-hydroxytamoxifen (0, 4, 8, 24, 
30hrs) to increase the nuclear MycER protein levels. Thus, we analyzed 
PUMA and SAE1 expression in mammospheres in response to Myc activation. 
As shown in figure 13 panel A and B, in mammospheres, SAE1 expression as 
well as NUC and CAD, known Myc targets, increased in response to Myc 
activation after 8hrs of OHT treatment, in correspondence to the peak of the 
Myc expression levels, while at the same time point the levels of expression of 
PUMA are inhibited as previously described in RAT-MycER and in hT-RPE-
MycER cells. As previously described, PUMA activation is dependent by a 
functional p53 and mediated by a p53-responsive element in its promoter. 
! '"!
Indeed, to address the Myc-mediated regulation of PUMA, we analyzed either 
the expression of common Myc and p53-targets genes (p21 and GADD45a) 
and only p53-targets (BAX and NOXA) (Figure 14). The activation of p53 
protein is evident at later time points of Myc induction, highlighting the p53-
dependent regulation of Myc during the self-renewal in normal stem cells.  
Collectively, these data determined that the expression of SAE1 and PUMA 
depends on Myc activity. In particular, we have established that SAE1 and 
PUMA expression is always inversely correlated. 
 
 
  
 
 
 
 
Figure 13. Myc regulates PUMA and SAE1 expression. (A) mRNA expression levels of PUMA and SAE1, 
were quantified by qRT –PCR in wt mammospheres infected with empty vector and MycER lentivirus (0h) and 
after 4, 8, 24, 30 hrs of treatment with OHT. (B) Myc targets expression NUC and CAD were measured in wt 
mammospheres infected with MycER lentivirus and then treated or not (0h) with OHT (4, 8, 24, and 30 hrs); Myc 
expression was measured by qRT–PCR using with specific hMyc oligos. Values were compared to empty vector 
infecting mammospheres. 
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Figure 14. The expression profile obtained demonstrates that p53 pathway is activated after 24hrs of 
OHT treatment in mammospheres infected with MycER vector; mRNA expression levels of GADD45a 
and p21 were quantified by qRT–PCR in wt mammospheres infected with empty vector or MycER 
lentivirus (0h) and after 4, 8, 24, 30hrs of treatment with OHT. MDM2 displays a peak of expression at 
8h, whereas NOXA and BAX show little variation in levels of expression in respect to cells not treated 
with OHT. The maximum phosphorylation level of of serine 15 of p53 that corresponds to the active form 
of p53 was seen at 24h. 
! ''!
in this system, p53 role in self-renewal is independent of Nanog
(P.G.P., unpublished data).
Loss of p53, Increased Frequency of Symmetric
Divisions, and Tumor Initiation
A role for p53 loss in mammary carcinogenesis is suggested by
the high proportion of breast cancers with p53mutations and the
prevalence of breast tumors in women with germline mutations
of p53. Although the mammary gland of p53 null mice is appar-
ently normal (Jerry et al., 1998) and p53 null mice rarely develop
mammary tumors (probably because of the early occurrence of
lymphomas), high incidence of mammary tumors develops after
somatic inactivation of p53 (Liu et al., 2007) or transplantation
into WT fat pads of the p53 null mammary epithelium (Jerry
et al., 2000; Kuperwasser et al., 2000). Thus, the p53 null
mammary epithelium contains increasing numbers of SCs and
is highly susceptible to tumor development, suggesting that
increased frequency of symmetric divisions might contribute to
mammary tumorigenesis in the p53 null mice by expanding the
pool of putative tumor target cells. Notably, the mammary gland
mass, which is likely to correlate with the number of mammary
SCs, is an important breast cancer risk factor (Trichopoulos
et al., 2008). Since p53 is a potent suppressor of mammary
transformation, an intriguing possibility is that inhibition of SC
symmetric divisions by p53 is one mechanism of tumor suppres-
sion in the mammary epithelium.
Loss of p53, Increased Frequency of Symmetric
Divisions, and Tumor Growth
We found that p53 signaling is attenuated in the ErbB2 tumor
mammospheres and that restoration of p53 by N3 provokes
the rapid exhaustion of cultured mammospheres and reduces
tumor growth in vivo. Analysis of biological mechanisms
suggests that the antitumor activity of N3 is due to a selective
effect of the drug on the self-renewing divisions of ErbB2 tumor
SCs. First, N3 converted the prevailing mode of division of
ErbB2 tumor SCs from symmetric to asymmetric. Consistently,
the frequency of ErbB2 tumor SCs decreased dramatically in
culturedmammospheres and primary tumors after N3 treatment.
Furthermore, N3 did not induce apoptosis in either ErbB2
mammospheres or primary tumors, nor did it reduce the fraction
of proliferating cells. Together, these data imply that increased
frequency of symmetric divisions and extended replicative
potential of ErbB2 tumor SCs contribute to tumor growth in vivo.
Therapeutic Efficacy of p53 Restoration in Cancer SCs
Three groups have recently reported that re-expression of p53
causes regression of different p53 null tumors, including
lymphomas, sarcomas, and hepatocellular carcinomas (Martins
et al., 2006; Ventura et al., 2007; Xue et al., 2007). We show that
this can be achieved also with drugs that target p53 in tumors
carrying WT p53 alleles and attenuated p53 signaling, a situation
that is common to !50% of human cancers. Our findings,
Figure 6. Modeled Kinetics of SC Divisions
within Normal and ErbB2 Tumor Mammo-
spheres
The models represent the kinetics of cell divisions
during the clonal expansion of one normal (A) or
ErbB2-tumor (B) mammosphere-initiating cell
(MIC). Each (WT or ErbB2) scheme reports the
proliferative history of one MIC (upper part), the
projected cellular composition of the formedmam-
mosphere (middle part), and the progressive
decrease of PKH fluorescence intensity (PKH
gradient). The mathematical model was based on
the assumptions that (1) WT mammospheres
contain 1 PKHhigh SC (through at least one prior
division) and (2) ErbB2 tumor mammospheres
contain seven SCs, of which: two in the PKHhigh
subset (via at least two prior cell divisions), four in
the PKHlow (via at least four to seven prior divi-
sions), and one in the PKHneg (via at least nine
to 11 prior divisions), as obtained by elaborating
experimental data (Table S5). The mathematical
model predicted that, in WT mammospheres, the
PKHhigh SC underwent at least one asymmetric
division, as expected. For cancer SCs, instead, it
predicted (1) one symmetric division of the ErbB2
tumor MIC (red arrow) to generate two daughter
SCs with equal proliferative potential (D1 and D2;
only the expansion of D1 is shown in the graph);
(2) one symmetric division of D1 (red arrows) to
generate one PKHhigh SC and one SC that divides
further to generate PKHlow and PKHneg SCs; (3)
alternation of two symmetric and three asymmetric
(black arrows) divisions to generate two PKHlow
SCs and one SC that proliferate further; and (4)
three additional rounds of asymmetric divisions
to generate one PKHneg SC. Pr, progenitor.
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4.3.1 PUMA and SAE1 expression after reprogramming of homogeneous 
mouse mammary cells into stem cells mediated by Myc 
Since SAE1 protein seems to play ad important role in the Myc-synthetic lethal 
(MySL) phenotype observed using shRNAs in human mammary epithelial 
cells, as reported by Kessler et al. (2012), it appeared intriguing to study the 
expression of these Myc targets in homogeneous population of mammary 
progenitor cells, obtained using a previously described with a PKH26-based 
label-retaining protocol (Figure 15). The primary mammary cells were pulse-
labeled with PKH26 and then cultured as mammospheres for one passage, 
followed by flowsorting of PKH26-high cells (about 1.07 % of all cells, 
representing stem cells) and PKH26-negative cells (about 70% of all cells, 
representing progenitor cells) (Figure 15A). The PKH26-negative cells were 
then infected with a control lentivirus or a lentivirus-expressing MycER 
(Littlewood et al. 1995). Five thousand infected cells were cultured under non-
adherent conditions to generate mammospheres, which were then passaged on 
a weekly basis. The control infected progenitor cells formed mammospheres 
with very low efficiency even at the first passage and both the mammospheres 
number and the cumulative cell number declined to practically zero within a 
few passages (Figure 16C). In contrast, the MycER-expressing progenitor cells 
were reprogrammed into mammary stem cells, as determined by their ability to 
form mammospheres (Figure 16B). Unexpectedly, PUMA expression was 
upregulated in the presence of MycER, while SAE1 expression was unchanged 
(Figure 16D). As shown in figure 16, in mammospheres, PUMA expression as 
well as the known NUC and CAD genes, increase in response to Myc 
activation. The PUMA activation can be caused by p53-activation, indeed, p53 
targets (p21 and BAX) are upregulated in response to Myc activation (Panel F 
and G). 
 
  
Figure 15. Modeled Kinetics of stem cell devisions within Normal Mammospheres The model repre ents 
the kinetics of cell divisions during the clonal expansion of one normal mammosphere-initiating cell (MIC). The 
scheme reports the proliferative history of one of mammosphere initating cell (upper part), the projected cellular 
composition of the formed mammospheres (middle part), and the progressive decrease of PKH fluorescence 
intensity (PKH gradient) (Cicalese et al. 2009).!
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Figure 16. Reprogramming of progenitor mammary cells to stem cells by MycER (A and B) FACS 
distribution of PKH high, PKH low, and PKH neg cells and image of M3 mammospheres obtained after 
replating and infection with MycER–lentivirus of PKH neg cells. (C) PKH26-negative cells, which are 
devoid of stem cells, were isolated from secondary mammospheres and infected with a lentivirus-
expressing MycER or with a control virus (Empty vector). The cells were cultured under non-adherent 
conditions and mammospheres number and cumulative cell number were determined at each passage. 
Results are presented as means +/-SD. (D) PUMA and SAE1 expression was measured in wt 
mammospheres one week post-infection with MycER lentivirus or the corresponding empty vector. The 
espression profile obtained demonstrates an activation of proapoptotic p53 targets (F and G) and this 
phenotype obscured the downregulation of PUMA and upregulation of SAE1 that we expected to see, 
albeit we have successfully induced Myc expression and its classical downstream targets (e.g. NUC and 
CAD) (E). 
D!
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Conclusions 
 
The abrogation of FOXO3a function promotes foci formation 
by Myc in vitro, and dramatically accelerates Myc driven lymphomagenesis in 
vivo (Bouchard et al. 2001; Bouchard et al. 2004). In this study we provide a 
suitable explanation for this behavior, demonstrating strong evidence for the 
cooperation between Myc and PI3/AKT/FOXO3a pathways in the activation of 
Myc targets. Our findings propose that the synergy between Myc and 
PI3/AKT/FOXO3a pathway has an important role not only in the activation of 
multiple Myc target genes involved in cell proliferation, but also in repression 
of FOXO3a targets involved in anti-proliferative function such as PUMA and 
GADD45a. Reciprocal control by Myc and FOXO3a has been also described 
in the regulation of p27Kip1 transcription (Chandramohan et al. 2008; Dijkers 
et al. 2000; Stahl et al. 2002), and it has been suggested that Myc inhibits p27 
transcription via physical association with FOXO3a (Chandramohan et al. 
2008). The significant overlap between FOXO3a and Myc targets includes 
CyclinD2, CDK4 CyclinE2 growth-promoting factors and PUMA, p27Kip1 
and GADD45a growth-arrest factors. Our findings provide a mechanistic 
model for explaining the cooperation of Myc and PI3/AKT-signaling in 
repression of FOXO3a-dependent activation. Serum external growth factors 
induce activation of the AKT survival kinase leading to phosphorylation of 
FOXO3a. However, AKT activation is not fully sufficient to repress FOXO3a 
targets and it contributes further to repression by establishing the repressive 
chromatin marks characterized by deacetylation of H3/H4 histones and 
increased levels of H4K9me2. The inhibition of FOXO3a-mediated activation 
of PUMA, by aberrant expression of Myc correlates with functional 
relationship between PUMA and Myc. PUMA has been proposed as a tumor 
modifier gene that limits lymphomagenesis. Using genetically defined mice it 
was shown that PUMA plays a physiological role in suppressing Myc-induced 
murine B-cell lymphomagenesis, and PUMA deficiency alleviates Myc-
induced apoptosis and accelerates Myc lymphomagenesis. The importance of 
the Myc-role in tumor cells is highlighted of the pervasive nature of Myc 
regulatory network. Indeed, recently, it has been documented that a specific 
pathway involving SAE1/2, a critical component of the SUMO activating 
enzyme genes, is required to support Myc-addicted tumors. Thus, Sae1/2 acts 
as Myc-synthetic lethal in Myc-driven tumors; inhibition of SAE triggers 
mitotic spindle defects in Myc-expressing cells, eliciting mis-segregation of 
chromosomes and commitment to apoptosis (Kessler et al. 2012). Our study 
adds news insight in this context since we show that Myc directly activates 
SAE1 transcription, suggesting that its oncogenic SAE1-dependent activity is 
ensured by Myc itself through direct binding and transcriptional activation of 
SAE1 expression. Thus, recruitment of Myc on SAE1 modulates its expression 
supporting Myc oncogenic program by activation of sumoylation-dependent 
Myc-switchers. Intriguing is the fact that PUMA and SAE1 are adjacent on the 
human chromosome 19 and that their expression has been always found 
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inversely correlated. While Myc cooperates with PI3/AKT pathway to repress 
PUMA transcription, hyper activation of Myc activates SAE1 transcription. 
Since the apparent parallels between tumor cells and normal stem cells, we had 
a great interest in the study of the transcriptional regulation of PUMA and 
SAE1 during Myc driven reprogramming. Our data show that Myc is able to 
regulate the transcription of PUMA and SAE1 in a heterogeneous population 
of mouse mammary progenitor cells after reprogramming into mammary stem 
cells. The regulation of PUMA and SAE1 is inversely correlated as in other 
models utilized. In particular, PUMA is down regulated in mammospheres 
with high expression of Myc, whilst SAE1 is upregulated at the same condition 
of Myc expression. The regulation of these two Myc-targets is correlated with 
the profile of expression of p53 targets. Accordingly, we found no activation of 
the proapoptotic p53 downstream effectors.  
A recent review has postulated that in normal stem cells and cancer stem cells, 
Myc expression alone sustains a pool of expanding stem cells in the absence of 
transformation or apoptosis (Verga Falzacappa et al. 2012). Indeed, Myc 
expression in mammary stem cells mimics the loss or attenuation of p53. On 
the other end, the expression profile obtained in a homogeneous population of 
progenitor cells (PKHneg cells) after Myc-reprogramming demonstrated an 
absence of inversely correlation of expression between PUMA and SAE1, 
albeit we have successfully induced Myc expression and its classical 
downstream targets (e.g. NUC and CAD). The activation of proapoptotic p53, 
as demonstrated by up-regulation of p21, BAX and PUMA, supports the 
observation that Myc is not able to interfere with p53-mediated activation of 
PUMA, as seen in RAT-MycER model.  
Nevertheless the relevance role of Myc during reprogramming of somatic stem 
cells, the molecular mechanisms by which it operates is not understood and 
further investigations will be necessary to understand the role of these Myc 
targets, nonetheless it is recognized the crucial role of p53-Myc axis in 
regulating normal stem cell and cancer stem cell pool.
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ABSTRACT
Growth factor withdrawal inhibits cell cycle progres-
sion by stimulating expression of growth-arresting
genes through the activation of Forkhead box O
transcription factors such as FOXO3a, which binds
to the FHRE-responsive elements of a number of
target genes such as PUMA and GADD45a.
Following exposure of cells to growth factors
FOXO3a-mediated transcription is rapidly repressed.
We determined that repression correlates with acti-
vation of PI3K/AKT pathway leading to FOXO3a
phosphorylation and release of FOXO3a protein
from PUMA and GADD45a chromatin. We show
here that Myc significantly and selectively contrib-
utes to repression of FOXO-mediated expression of
PUMA and GADD45a. We found that in Myc deprived
cells inhibition of PUMA and GADD45a following
serum stimulation is impaired and that Myc does
not interfere with p53 induction of PUMA transcrip-
tion. We observed that following activation, Myc is
rapidly recruited to PUMA and GADD45a chromatin,
with a concomitant switch in promoter occupancy
from FOXO3a to Myc. Myc recruitment stimulates
deacetylation of Histone H3 and H4 and methylation
of lysine 9 in H3 (H3K9me2) on both PUMA and
GADD45 chromatin. These data highlight a Myc role
on cell growth by selectively inhibiting FOXO3a
induced transcription of PUMA and GADD45.
INTRODUCTION
FOXO transcription factors, through direct binding to the
cognate FHRE sites, direct expression of gene targets
governing cell cycle arrest, apoptosis, metabolism, differ-
entiation and oxidative defense. FOXO factors are regu-
lated through the phosphatidylinositol 3-kinase (PI3-K)
pathway. In the absence of growth factors, FOXOs are
localized to the nucleous and transcriptionally active
(1–3). Activation of AKT in response to growth factor
stimulation induces phosphorylation of FOXOs at three
highly conserved serine and threonine residues (2).
Because the PI3K-AKT axis is activated in virtually all
human cancers, FOXO proteins result frequently inactiv-
ated in cancer cells (4) and murine genetic studies provided
formal proof of the role of FOXOs in tumor suppression
(5,6). Constitutive FOXO3a activation results in the re-
pression of Myc target genes (6–8), suppression of Myc-
driven lymphomagenesis and activation of cell cycle arrest
and apopotsis in human renal cell carcinoma (6,9).
FOXO-mediated inhibition of Myc-target genes appears
to operate through induction of Mxi1-SRa and mir-145
(7,8). It has been suggested that FOXO3a and Myc might
co-regulate a common set of targets through their recruit-
ment to the respective cognate binding sites present on the
same sequences. Accordingly, there is a signiﬁcant overlap
between FOXO3a and Myc targets including growth-
promoting factors CyclinD2, CDK4, CyclinE2 (7)
and growth-arrest factors such as PUMA (10), p27kip1
(11–14) and GADD45a (15,16) suggesting that FOXO3a
and Myc might reciprocally regulate a common set of genes.
Here, we evaluate if Myc can interfere with FOXO3a-
dependent transcription of two targets, the proapoptotic
BBC3/PUMA (10) and the DNA damage-responsive
GADD45a (15). Using a conditional Myc expression sys-
tem, we determined that in response to serum withdrawal,
PUMA and GADD45 expression is upregulated by
FOXO3a-dependent activation. Following cell growth
stimulation and Myc activation, we found that Myc is
rapidly recruited to PUMA and GADD45a chromatin,
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with a concomitant switch in promoter occupancy from
FOXO3a to Myc. Myc recruitment signiﬁcantly and se-
lectively contributes to repression of FOXO-mediated ex-
pression of PUMA and GADD45a and its presence on
both PUMA and GADD45 chromatin correlates with in-
duction of histone repressive marks such as deacetylation
of Histone H3 and H4 and methylation of lysine 9 in H3
(H3K9me2) at these targets.
MATERIALS AND METHODS
Cell culture and drugs
RAT1 cells expressing a 4-hydroxytamoxifen (OHT)-indu-
cible MycER chimera (17), RAT1 and RAT-Myc/ cells
were cultured in DMEM medium supplemented with 10%
fetal calf serum. Cells were made quiescent by contact in-
hibition followed by serum removal for 2 days. To induce
entry into the cycle, synchronized growth-arrested cells
were treated with OHT (1mM) alone or OHT plus
serum or serum alone as indicated in the text and har-
vested at the indicated times. The AKT-inhibitor
LY294002 (10mM) was added in the media where
indicated. mRNA expression was quantiﬁed by qRT–
PCR (see below) and compared to quiescent cells.
mRNA levels were normalized to b-glucuronidase
(GUS) mRNA levels (18,19). Growing RAT-MycER
cells were treated with OHT for Myc induction (Myc)
for 4 h. OHT-treated and control-untreated cells were
incubated with CPT (12mM for 4 h) or Nutlin-3 (10mM
for 4 h) and then PUMA and/or GADD45a mRNA levels
were quantiﬁed by qPCR as described below.
Transfections and siRNA
To carry out transient transfection experiments in RAT1
and RAT-MycER cells (19), we used MicroPoRATor
Digital Bio Technology, a pipette-type electroporation.
Indicated plasmids, DNAs or siRNA were introduced
into each 3 106 dissociated cells in 100 ml volume accord-
ing to manufacturer’s instructions. Pulse width was deter-
mined according to applied voltages: 1400V, 30ms, 1pulse.
Electroporated cells were then seeded into 100-mm culture
dishes containing 5ml of culture media. After 5 h of recov-
ery, the cells were serum deprived for 48 h. For siRNA
treatments, ON-TARGETplus SMARTpool (L-003282-
00-0005) Myc; and ON-TARGETplus Non-targeting
pool (D-001810-10-5) were obtained from Dharmacon.
An amount of 100 nM, ﬁnal concentration of the pools,
was used for each transfection. Expression of proteins was
determined by western blot. In transfection experiments,
RAT-MycER cells were transfected with the 3 mg of
FOXO3a-TM vector expressing a constitutively active
FOXO3a by electroporation as described (19) after 5 h
of recovery, the cells were serum deprived for 48 h and
mRNA levels were evaluated 1 and 4 h after treatment
with serum and OHT.
mRNA quantiﬁcation by qPCR
cDNA was prepared from total RNA with the Quantitect
Reverse Transcription Kit (Qiagen) according to
manufactory instructions. Each sample was assayed in
triplicate. Oligoprimers are described in Supplementary
Data. The qPCR data were normalized to the expression
of the housekeeping b-glucuronidase (GUS) gene and
after normalization the data were presented as fold
change relative to the 0 point.
Quantitative chromatin immunoprecipitation
Quantitative chromatin immunoprecipitation (qChIP) ex-
periments were performed essentially as described (18,19).
For qPCR, 3 ml out of 150 ml of immunoprecipitated DNA
was used with primers described in Supplementary Data.
ACHR promoter amplicon was used as negative control
in all experiments. Normal serum and input DNA values
were used to subtract/normalize the values from qChIP
samples by using: % Input=2DCt 3; DCt=Ct(input)-
Ct(cIP) (18,19). qRT–PCR and qChIP data are presented
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Figure 1. Myc inhibits FOXO3a-dependent transcription.
Asynchronous RAT-MycER growing cells (Gr) were serum deprived
for 2 days (0) and then treated with serum and OHT for 4 h.
(A) Protein expression is shown in immunoblots of whole-cell extracts
with anti-PUMA, anti-GADD45, anti-Phospho-FOXO3a,
anti-FOXO3a and actin for loading control. (B) mRNA expression
levels of PUMA and GADD45 were quantiﬁed by qRT–PCR in asyn-
chronous RAT-MycER growing cells (Gr), quiescent (0) and after 1
and 4 h of treatment with serum and OHT. mRNA levels were
normalized to b-glucuronidase (GUS) mRNA levels. All values repre-
sent the average of at least three independent experiments. Error bars
indicate SD. (C) RAT-MycER cells were transfected with the
FOXO3a-TM vector expressing a constitutively active FOXO3a by
electroporation as described; after 5 h of recovery, the cells were
serum deprived for 48 h and mRNA levels were evaluated 1 and 4 h
after Myc induction in the presence of serum +OHT. The
AKT-inhibitor LY294002 (10mM) was added to the media where
indicated. mRNA expression was quantiﬁed by qRT–PCR and
compared to quiescent cells. mRNA levels were normalized to
b-glucuronidase (GUS) mRNA levels. All values represent the
average SD (n=3). Error bars are standard error of the mean.
*P< 005, **P< 001.
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Figure 2. Myc knockdown prevents repression of FOXO3a targets. (A) Serum deprived RAT-MycER cells (0) were treated for 4 h with OHT+
serum. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs. PUMA, GADD45
and Ncl mRNAs expression levels were quantiﬁed by qRT–PCR. Error bars indicate SD (n=3). Error bars are standard error of the mean.
*P< 005. The efﬁciency of Myc silencing by siRNA treatments measured by qRT–PCR and by immunoblot is shown on the right. (B) Quiescent
RAT-MycER cells were stimulated with OHT+serum (black square), with OHT alone (empty circle) or with serum alone (black triangles) and
expression levels of PUMA and GADD45 were quantiﬁed by reverse transcription and real-time PCR at the indicated times after treatment; values
were compared to quiescent cells and presented as means of two independent experiments each analyzed by triplicate qRT–PCR. (C) RAT-Myc/
cells as well as cells transfected with a Myc expression vector were serum deprived for 48 h and PUMA and GADD45 mRNA levels were evaluated
by qRT–PCR 4h after serum induction. Values were compared to quiescent cells. (D) Serum deprived (2 days) RAT1 cells (O) were treated with
serum (10%) for 4 h. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs.
PUMA and GADD45 mRNAs expression levels were quantiﬁed by qRT–PCR. Error bars indicate SD (n=3), *P< 005. The efﬁciency of Myc
silencing by siRNA treatments measured by immunoblot is shown on the bottom.
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as means of three at least independent biological ex-
periments each analyzed by triplicate (SD). Statistical
signiﬁcance was determined using the matched pairs test.
RESULTS
Myc contributes to repression of PUMA and GADD45
expression following growth stimulation
To investigate how Myc could inﬂuence FOXO3a-
dependent transcription we used the RAT-MycER ﬁbro-
blast cell line (18) in which the inducible MycER protein is
activated upon treatment with tamoxifen (OHT). PUMA
and GADD45a expression was monitored in asynchron-
ous RAT-MycER cells, and in cells that were serum
deprived for 2 days and then treated with OHT/serum
for cell cycle reentry andMyc activation. As largely expected,
PUMA and GADD45a expression is upregulated in re-
sponse to growth factor deprivation, and addition of
serum inhibits their expression (Figure 1A and B). In the
absence of serum, the phosphoinositide 3-kinase PI3K/
AKT pathway is inactive and FOXO3a remains unphos-
phorylated into the nucleus where it activates target genes
(1,2). FOXO3a phosphorylation is inhibited by serum
withdrawal and phosphorylation is restored 4 h after
serum addition (Figure 1A). Moreover, the presence of
the PI3-K inhibitor LY294002 or the overexpression of the
constitutively active FOXO3a-TM, prevents PUMA and
GADD45a repression by serum (Figure 1C). Collectively,
these data indicate that activation of FOXO3a in serum-
deprived RAT-MycER ﬁbroblasts stimulates the expres-
sion of growth-arrested genes PUMA and GADD45a;
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Figure 3. Myc, FOXO3a and Rpb1occupancy on PUMA and GADD45 chromatin. Asynchronous RAT-MycER growing cells (Gr) were serum
deprived for 2 days (00) and then treated with serum and OHT serum for Myc activation at the indicated times (300, 600 and 2400). qChIP was
performed using antibodies recognizing FOXO3a (A), Myc (B) and Rpb1 (C). The amplicons used are reported in Supplementary Data. (D)
FOXO3a occupancy on PUMA and GADD45 chromatin in growing (Gr) starved (00) and serum treated (600 and 2400) RAT Myc/ cells.
ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons reported in Supplementary Data. The values reported were calculated
as fold percentage of amount of immunoprecipitated DNA relative to that present in total input chromatin. All qChIP data are presented as mean of
at least three independent biological experiments each analyzed by triplicate SDs. ACHR promoter amplicon was used as negative control in all
experiments.
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conversely, cell growth stimulation by serum is accom-
panied by repression of FOXO3a-dependent expression
of these negative regulators of cell proliferation.
Because RAT-MycER cells express a conditional
activated Myc protein, we sought to determine the relative
contribution of Myc in the repression of FOXO3a target
genes. We ﬁnd that silencing of Myc with speciﬁc siRNA
restores PUMA and GADD45a expression to levels com-
parable to that observed in serum-starved cells (Figure 2,
panel A). As control, Myc silencing strongly reduces the
expression of Nucleolin (NCL), a well-deﬁned target for
Myc activation (19). In serum-tarved cells, we did not
detect signiﬁcant differences on the relative levels of
mRNA in samples treated with siCtl or siMyc, suggesting
that in serum-starved cells, expression of both PUMA and
GADD45 is largely independent from Myc. To determine
the relative contribution of serum and Myc activation of
the repression of PUMA and GADD5a, we compared the
relative levels of expression in cells that were treated with
serum alone, OHT and serum+OHT treatments. We
found that Myc is able to repress FOXO3a-target genes
even in the absence of serum, although under these con-
ditions the kinetic of inhibition is slower (Figure 2B). On
the other hand, serum does not fully substitute for Myc in
the repression of PUMA and GADD45, because in
RAT-Myc/ cells serum addition does not fully repress
FOXO3a-targets (Figure 2C); however, a robust repres-
sion of PUMA and GADD45a mRNA levels were restored
in RAT-Myc/ in which a Myc expression vector has
been transfected (Figure 2C). To further investigate the
endogenous Myc activity in response to serum addition,
we monitored PUMA and GADD45a expression in RAT1
cells that were serum deprived for 2 days and then treated
with serum for cell cycle re-entry. In response to serum
addition expression of both PUMA and GADD45a was
inhibited, and most importantly silencing of endogenous
Myc with speciﬁc siRNA restores PUMA and GADD45a
expression (Figure 2D). Collectively, these results high-
light a crucial contributory role of Myc in the inhibition
of FOXO3a-dependent gene expression in response to
growth factor stimulation.
FOXO3a and Myc occupancy on PUMA and GADD45
chromatin is mutually exclusive
Previous works showed that Myc represses GADD45a
through binding to the proximal promoter sequences
(15,16), and several high afﬁnity E-box sites for Myc
binding have been mapped upstream the ATG site of
PUMA (20–23), although a direct proof of Myc-binding
to these putative E-boxes has not been documented.
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Figure 4. Histone modiﬁcations on PUMA chromatin following Myc activation. RAT-MycER serum starved cells (00) are compared to cells induced
with OHT and serum for Myc activation (600). qChIP was performed using speciﬁc antibodies recognizing H3K4me3, H3K4me2, H3K9me3,
H3K9me2, H3Ac and H4Ac as indicated. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons surrounding PUMA
transcription start site (TSS) and E-BoxII (Supplementary Data). The qChIP data are presented as in Figure 3 and ChIP-enriched DNA was
quantiﬁed as previously indicated.
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Large-scale chromatin immunoprecipitation (ChIP)
studies showed that PUMA contains high afﬁnity E-box
sites for Myc binding, suggesting that PUMA may repre-
sent a putative direct target of Myc. Moreover, clustering
Myc target genes on the basis of histone modiﬁcation
marks, the PUMA E-boxes are characterized by high
levels of histone methylation at H3K4me3, a pre-requisite
for Myc binding and at H3K9me2, which is generally con-
sidered a repressive mark (24,25).
To assess Myc and FOXO3a occupancy on FOXO3a-
targets (PUMA and GADD45) we carried out qChIP
analysis in RAT-MycER growing cells (Gr), serum de-
prived for 2 days (00) and treated for 600 and 2400 with
OHT/serum. First of all we determined that the PUMA
E-boxII is the highest afﬁnity Myc binding site and that
Myc is recruited on this site rather early (600) after induc-
tion (Supplementary Figure S1). Accordingly to the induc-
tion of expression of PUMA after serum withdrawal
(Figure 1, panels A and B), recruitment of FOXO3a on
the FHRE sequence is found in serum-starved cells (00)
(Figure 3A). As soon as Myc is recruited on E-BoxII chro-
matin, FOXO3a disappears on PUMA chromatin. Similar
results are obtained by exploring GADD45 FHRE and
TSS for Foxo3a and Myc occupancy (Figure 3B). These
results indicate that upon cell cycle re-entry and Myc ac-
tivation, there is a concomitant switch in promoter
occupancy from FOXO3a to Myc resulting in transcrip-
tional repression. Accordingly we also determined that the
large subunit of RNAPII, Rpb1 occupancy at the tran-
scription start sites of both PUMA and GADD45 is
sharply reduced 600 after Myc activation (Figure 3C). To
address the relevance of serum on the reciprocal inhibition
of binding to the chromatin of Myc and FOXO3a we
performed a qChIP analysis in the RAT Myc/ cells of
FOXO3a occupancy in starved and serum-induced cells.
As shown in Figure 3D, FOXO3a occupancy of the
PUMA and GADD45a FHRE chromatin after 600 and
2400 is slightly affected by serum addition compared to
the strong reduction of FOXO3a observed in the
presence of Myc, suggesting a causative role of Myc in
the repression of FOXO3a-dependnet transcription.
Myc induces H3K9 methylation and H3–H4
de-acetylation on FOXO3a-targets chromatin
Myc responsive regions on the genome are characterized
by speciﬁc histones marks (20–22). High afﬁnity Myc
binding sites are marked by tri-methylation of lysine 4 in
the histone H3 tail. Upon Myc binding, changes in the
methylation and acetylation levels of histones H3 and
H4 have been correlated to the Myc positive or negative
effects on transcription efﬁciency of its targets (26,27). We
have performed qChIP assays to analyze histones
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Figure 5. Histone modiﬁcations on GADD45 chromatin following Myc activation. RAT-MycER serum starved cells (00) are compared to cells
induced with OHT and serum for Myc activation (600). qChIP was performed using speciﬁc antibodies recognizing H3K4me3, H3K4me2, H3K9me3,
H3K9me2, H3Ac and H4Ac as indicated. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons (Supplementary Data)
surrounding the TSS (332) and FHRE (+23). The qChIP data are presented as described in Figure 3.
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methylation and acetylation marks on PUMA TSS and
E-boxII sequences (Figure 4) and on GADD45 FHRE
and TSS sequences (Figure 5) following Myc binding.
We have focused our attention on the methylation
proﬁle of lysine 4 and 9 of histone H3 and on
pan-acetylation of histones H3 and H4. While
H3K4me3, H3K4me2 and H3K9me3 levels remain
largely unchanged, a robust increase of H3K9me2 is
found on PUMA TSS and E-BoxII upon treatment with
serum and MycER nuclear translocation by OHT treat-
ment (Figure 4). Concurrent with Myc binding, we also
detect a sharp reduction of H3- and H4-acetylated levels
on PUMA TSS and E-BoxII sequences (Figure 4). Similar
changes in chromatin modiﬁcations were found on the
chromatin of GADD45 gene (Figure 5).
However, the combined treatment of RAT-MycER cells
with OHT and serum does not allow to discriminate
between the effects of Myc activation and serum-induced
inactivation of FOXO3a. To deﬁne the relative contribu-
tion of Myc activation and serum, we carried out qChIP
assays in RAT1 cells that only express the endogenous
Myc analyzing histone modiﬁcations on GADD45 and
PUMA chromatin in serum starved versus serum-treated
cells. Comparing the ChIP data from RAT-MycER
(Figures 4 and 5) with RAT1 cells (Figure 6 and
Supplementary Figure S2) we ﬁnd, as consequence of
serum addiction to starved cells, a slower (4 h versus 1 h)
reduction of acetylated H3/H4Ac (Figure 6A and B) on
both PUMA and GADD45 chromatin (Supplementary
Figure S2), and increased levels of methylation of H3K9
(Figure 6C) in the RAT1 cells. Furthermore, to support
the relevant role of the endogenous Myc, we silenced Myc
expression in RAT1 cells and, as shown in Figure 6, panel
D, we ﬁnd that the levels of H3 and H4 acetylation are
largely unaffected in silenced cells, suggesting a causative
role of Myc in the H3/H4 reduction following serum
stimulation. To further support the role of Myc in the
loss of H3 and H4 acetylation, we have used RAT
Myc/ cells to analyze H3/H4Ac occupancy on
FOXO3a-targets. In this Myc null cell line, after 600 and
2400 of serum starvation, H3/H4Ac occupancy of the both
PUMA and GADD45 chromatin is largely unaffected,
consistent with a relevant role of Myc in the reduction
of H3- and H4-acetylated levels of both PUMA and
GADD45 (Figure 7A). Finally, inhibition of histone
deacetylases by TSA severely impairs Myc inhibitory
effect on PUMA and GADD45 expression, following
Myc induction (Figure 7B and C). These data indicate
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Figure 6. Myc is required for histone modiﬁcation of PUMA chromatin. Asynchronous RAT1 growing cells were serum-deprived for 2 days (00) and
then treated with serum (10%) and samples collected at the indicated times (300, 600 and 2400) and qChIP was performed using speciﬁc antibodies
recognizing H3Ac, H4Ac and H3K9me2, as indicated in panels A, B and C. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using
amplicons surrounding PUMA, TSS and E-BoxII. The qChIP data are presented as in Figure 3. (D and E) Serum deprived (2 days) RAT1 cells (O)
were treated with serum (10%) for 4 h. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as
scrambled RNAs. qChIP was performed using antibody recognizing H4Ac, and ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using
amplicons surrounding PUMA and GADD45 TSS as indicated. Error bars indicate SD (n=3). The efﬁciency of Myc silencing by siRNA treatments
measured by qRT–PCR is shown in (F).
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that Myc binding on PUMA and GADD45 regulatory
regions correlates with increased methylation of H3K9
and with deacetylation of H3/H4.
Myc does not interfere with p53-mediated
activation of PUMA
We sought to determine the speciﬁcity of Myc repressive
effect on PUMA transcription independently from
FOXO3a activation. PUMA expression following DNA
damage is stimulated by p53 binding through consensus
p53-responsive elements located within its promoter
(23 and references therein). To determine whether Myc
might suppress p53-mediated activation of PUMA, we
analyzed the effect of Myc in the presence of active p53.
p53 is activated by the DNA damaging compound
Camptothecin (CPT) or by Nutlin-3, which disrupting
p53-MDM2 interaction releases the active form of p53
(28). Asynchronous RAT-MycER growing cells were
treated with CPT or Nutlin-3 for 4 h prior to Myc activa-
tion and PUMA mRNA levels were quantiﬁed by qRT–
PCR (Figure 8A). Both CPT and Nutlin-3 treatments
activate PUMA expression in the presence or absence of
Myc. Next, we performed qChIP assays to analyze the
occupancy of Myc and Rpb1 on PUMA regulatory
regions following p53 activation by CPT and Nutlin-3.
Figure 8B demonstrates that in condition in which CPT
and Nutlin-3 activate PUMA, E-box occupancy by Myc
is unaffected. Accordingly, TSS occupancy by Rpb1 in
cells treated for p53 activation (CPT or Nutlin-3)
remains unchanged after Myc activation (Figure 8C).
These data demonstrate that Myc binding does not inter-
fere with p53-mediated activation of PUMA and indi-
cate that Myc is not a global repressor of PUMA
expression.
DISCUSSION
In this report, we show that Myc and the PI3/AKT
pathway cooperate in the repression of FOXO3a-
dependent gene activation. Compelling evidences strongly
suggest that Myc and PI3/AKT/FOXO3a pathways co-
operate in the activation of Myc target genes, and abro-
gation of FOXO function promotes focus formation by
Myc in vitro, and dramatically accelerates Myc-driven
lymphomagenesis in vivo (7–9). Recent studies provided
evidences that FOXO-mediated inhibition of Myc func-
tions operates via suppression of Myc through upregula-
tion of the Myc antagonists, Mxi1-SRa and mir-145 (6).
The ﬁndings reported here suggest that the synergy
between Myc and PI3/AKT/FOXO3a pathway has an
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impairs Myc inhibitory effect on PUMA (B) and GADD45 (C) activated transcription. Serum-deprived RAT-MycER cells (0) were treated for 600
and 2400 with OHT+ serum in presence or absence of TSA (0.2 mg/ml) as indicated. PUMA and GADD45 expression levels were quantiﬁed by qRT–
PCR. Error bars indicate SD (n=3), *P< 0.01.
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important role not only in the activation of multiple Myc
target genes involved in cell proliferation, but also in re-
pression of FOXO3a targets involved in anti-proliferative
function such as PUMA and GADD45a. Reciprocal
control by Myc and FOXO3a has been also described in
the regulation of p27Kip1transcription (11–13), and it has
been suggested that Myc inhibits p27 transcription via
physical association with FOXO3a (14). The presence of
Myc on PUMA or GADD45a chromatin in the absence
of FOXO3a, suggests that Myc recruitment does not
rely on a physical FOXO3a/Myc interaction. Moreover,
several attempts to detect interaction between Myc and
FOXO3a using both endogenous and over-expressed
proteins failed (data not shown), and we conclude that
the divergent FOXO3a and Myc-mediated regulation of
targets genes requires the recruitment of these factors in an
independent and mutually exclusive manner. Indeed, there
is a signiﬁcant overlap between FOXO3a and Myc targets
including growth-promoting factors CyclinD2, CDK4
CyclinE2 and growth-arrest factors such as PUMA,
p27kip1 and GADD45a. It is highly suggestive that the
opposite activity of FOXO3a and Myc proteins on
common targets will profoundly affect the proliferation
of normal and tumor cells (Figure 8D).
Our ﬁndings provide a mechanistic model for under-
standing the cooperation of Myc and PI3/AKT-signaling
in repression of FOXO3a-dependent activation. First, in
response to serum withdrawal PUMA and GADD45a are
activated at transcriptional level and binding of active
FOXO3a to the cognate FHRE sites is largely responsible
for this effect. Serum external growth factors induce acti-
vation of the survival kinase AKT leading to phosphoryl-
ation of FOXO3a. However, AKT activation is not fully
sufﬁcient to repress FOXO-3a-dependent transcription.
Myc binding to the FOXO3a targets further contributes
to repression by establishing the repressive chromatin
marks characterized by deacetylation of H3/H4 histones
and increased levels of H4K9me2.
It has been recently reported that Myc-mediated repres-
sion of GADD153 and Id2 genes involves direct Myc
binding to the E-box and a process that involves histone
deacetylation (29). The ﬁndings reported here strongly
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suggest that Myc-mediated repression of FOXO3a-
dependent transcription correlates with induction of
repressive epigenetic changes of target genes.
Following Myc activation, FOXO3a-mediated tran-
scription is shut off and concurrently a robust increase
of H3K9me2 (likely due to H3K9me1 methylation) and
de-acetylation of H3 and H4 occurs on FOXO3a targets.
Further investigations will be necessary to identify the H3/
H4 de-acetylase and H3K9 methylase responsible of Myc
mediated changes of FOXO3a target genes chromatin.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures S1–S2, Supplementary Methods.
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Introduction 
 
c-Myc is a regulatory gene that codes for a basic 
helix-loop-helix transcription factor (Myc) that 
can both activate and repress transcription. Myc 
activates transcription of dedicated target 
genes as component of the Myc/Max complex, 
which binds to specific DNA sequences, termed 
E-box [1, 2]. Oncogenic activation of Myc pro-
motes regulation of a plethora of genes in the 
cell and the delicate balance of pro and anti 
tumorigenic properties of its targets defines the 
fate of the cells. Understanding the Myc-driven 
transcriptional program represent one of the 
most challenging aspect to decipher the mo-
lecular mechanisms underlying Myc-induced 
tumorigenesis [2, 3].  
 
Here we report a novel and important target of 
Myc activity. We found that SAE1 transcription is 
activated by Myc through recruitment to E-box 
sequences located at SAE1 transcriptional start 
site. SAE1 in association with SAE2 form a criti-
cal component of the sole SUMO-activating en-
zyme necessary for SUMO conjugation to pro-
teins [4]. SAE1 together with its partner SAE2/
UBA2 has been recently shown to be necessary 
for the tumorigenicity of Myc-dependent cancer 
cells in vitro and in vivo [5], and most impor-
tantly gene expression analysis of Myc-high hu-
man breast cancer suggested that low SAE1/2 
abundance in the tumors correlates with longer 
survival of the patients [5]. The findings re-
ported here, showing that Myc directly activates 
SAE1 transcription, add new insight in this con-
text, suggesting that Myc oncogenic activity 
which depends on SAE1 is ensured by Myc itself 
through direct binding and transcriptional acti-
vation of SAE1 expression.  
 
Materials and methods 
 
Cell culture and drugs 
 
RAT1 cells expressing a 4-hydroxytamoxifen 
(OHT)-inducible MycER chimera and RAT-Myc-/- 
cells were cultured in DMEM medium supple-
mented with 10% fetal calf serum and MycER 
induction was carried out with OHT (1µM) as 
recently described [6, 7]. Cells were made qui-
escent by contact inhibition followed by serum 
removal for two days. To induce entry into the 
cycle, synchronized Go arrested cells were 
treated alone or OHT plus serum or serum alone 
as indicated in the text and harvested at the 
indicated times. Human retinal hT-RPE-MycER 
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cell lines in which the inducible Myc-estrogen 
receptor fusion transgene (MycER protein) is 
activated upon treatment with tamoxifen (OHT) 
were grown and OHT-treated as recently de-
scribed [8]. 
 
Transfections and siRNA 
 
To carry out transient transfection experiments 
in RAT-Myc-/- and RAT-MycER cells, we used 
MicroPoRATor Digital Bio Technology, a pipette-
type electroporation [6, 7]. Indicated plasmids, 
DNAs or siRNA were introduced into each 3X106
-dissociated cells in 100-µl volume according to 
manufacturer’s instructions. For siRNA treat-
ments, ON-TARGETplus SMARTpool (L-003282-
00-0005) Myc; and ON-TARGETplus Non-
targeting pool (D-001810-10-5) were obtained 
from Dharmacon.  
 
mRNA quantification by qPCR 
 
cDNA was prepared from total RNA with the 
Quantitect Reverse Transcription Kit (Qiagen) 
according to manufactory instructions. Each 
sample was assayed in triplicate. The qPCR 
data were normalized to the expression of the 
housekeeping beta-glucuronidase (GUS) gene 
and after normalization the data were pre-
sented as fold change relative to the 0 point [6].  
 
Quantitative chromatin immunoprecipitation 
(qChIP) 
 
qChIP experiments were performed essentially 
as described [6, 7]. For qPCR 3µl out of 150µl 
of immunoprecipitated DNA was used with prim-
ers described in Supplementary Data. ACHR 
promoter amplicon was used as negative con-
trol in all experiments. Normal serum and input 
DNA values were used to subtract/normalize 
the values from qChIP samples by using: % In-
put = 2DCtx3; DCt = Ct(input)-Ct(cIP). qRT-PCR 
and qChIP data are presented as means of 
three at least independent biological experi-
ments each analyzed by triplicate (± SD).  
 
Results and discussion 
 
We have recently shown that the proapoptotic 
BBC3/PUMA (p53 up-regulated modulator of 
apoptosis) gene is a Myc target and through 
recruitment to an E-box binding site on its pro-
moter, Myc cooperates with the PI3/AKT path-
way to repress FOXO3a mediated activation of 
PUMA expression [7]. In the course of this study 
we were intrigued to observe a Myc responsive 
RNAPII peak in the second intron of PUMA locus 
in condition in which the PUMA expression was 
inhibited (data not shown). This finding 
prompted us to investigate the presence of ac-
tively expressed genes responsive to Myc activa-
tion in the region downstream of PUMA. Explor-
ing the genomic region downstream of PUMA 
locus we found the presence of SUMO-
activating enzyme SAE1 gene whose transcrip-
tion proceeds in the opposite strand to PUMA.  
 
To determine the expression of SAE1 in the 
presence of hyper-activated Myc protein, we 
Figure 1. Myc activates SAE1 expression. (A) mRNA expression levels of SAE1, NCL and PUMA were quantified by qRT
–PCR in quiescent cells (0) and after 4 and 6hrs of treatment with serum and OHT. (B) Myc expression was inhibited 
with specific siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs. SAE1 mRNAs expression 
levels were quantified by qRT–PCR in quiescent cells (0) and 6hrs of treatment with serum and OHT. The efficiency of 
Myc silencing by siRNA treatments measured by qRT–PCR is shown on the right. (C) RAT-Myc-/- cells as well as cells 
transfected with a Myc expression vector were serum deprived for 48 hrs. SAE1 mRNA levels were evaluated by qRT–
PCR 6 hrs after serum induction. Values were compared to quiescent cells (0).  
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used two Myc-inducible cell lines: the rat fibro-
blast RAT-MycER and the human retinal hT-RPE-
MycER cell lines in which the inducible Myc-
estrogen receptor fusion transgene (MycER pro-
tein) is activated upon treatment with tamoxifen 
(OHT) [6-8].  
 
As shown in Figure 1A, in RAT-MycER, SAE1 ex-
pression as well as the known Nucleolin (NCL) 
Myc target, increase in response to Myc activa-
tion while the levels of expression of PUMA are 
inhibited as previously described [6]. To deter-
mine the contribution of Myc in the SAE1 activa-
tion we silenced Myc expression by transfection 
of specific siRNAs in the RAT-MycER cells and 
we found that Myc silencing inhibits activation 
of SAE1 transcription (Figure 1B). To further 
determine the contribution of Myc in SAE1 acti-
vation, we used the isogenic RAT-Myc-/- cells 
and measured SAE1 expression levels in 
Figure 2. (A) hT-RPE-MycER cells were synchronized by 2 days of growth factors deprivation. SAE1, NCL and PUMA 
mRNAs expression levels were quantified by qRT–PCR in synchronized (0) and cells treated with growth factor + OHT 
(6hrs). All mRNA levels were normalized to β-glucuronidase (GUS) mRNA levels and all values represent the average 
of at least three independent experiments. Error bars indicate SD. Protein expression is shown in immunoblots of 
whole-cell extracts with anti-SAE1 and actin for loading control. (B) An adapted UCSC genome browser view of SAE1 
genomic sequence displaying H3K4me3 and H3K4me1 levels and putative E-box (asterisks). Myc occupancy on 
SAE1 and NCL chromatin in synchronized (0) and Myc induced hT-RPE-MycER cells for 6hrs is shown. ChIP-enriched 
DNA was quantified by real-time PCR analysis using amplicon covering the region containing the Myc binding E-boxes 
as shown in Figure 2A.  
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starved versus serum-induced cells. As shown in 
Figure 1C, SAE1 expression slightly increases 
upon serum addiction while the expression was 
significantly higher when a Myc expression vec-
tor was introduced by transfection into RAT-Myc-
/- cells. Collectively these results suggest that 
SAE1 expression is indeed regulated by Myc. 
 
SAE1 sequence is extremely conserved between 
rat and human suggesting an evolutionary fun-
damental role in cell physiology. In this respect 
we analyzed SAE1 expression in the retinal hu-
man Myc inducible cell line hT-RPE-MycER [8] 
and, as shown in Figure 2A, Myc activation re-
sults in induction of SAE1 expression at levels 
comparable to the known Nucleolin (NCL), a 
well defined Myc target. To explore the role of 
Myc in SAE1 activation we scanned its genomic 
sequences for putative Myc binding sites. Sev-
eral E-boxes were found, Figure 2B, and we fo-
calized our attention on two closely associated 
E-boxes in position close to the TSS site (-170 
and -101). Most importantly these E-boxes are 
located in a region with high level of H3K4Me3, 
a prerequisite for Myc binding (Figure 2B) [9, 
10]. To assess Myc occupancy on SAE1 we car-
ried out qChIP analysis in the RPE cells, which 
were growth factors-deprived for 2 days (0) and 
treated for 6hrs with OHT for Myc activation. 
Myc-immunoprecipitated chromatin was ana-
lyzed using amplicons spanning the SAE1 and 
NCL E-boxes and the qChIP data (Figure 2B) 
show that Myc is recruited on the E-box sites at 
the SAE1 promoter with efficiency comparable 
to recruitment on NCL. Although we cannot ex-
clude the presence of additional E-box binding 
sites that might contribute to Myc activation, we 
can conclude that SAE1 is a bona-fide positively 
regulated Myc target through a direct binding to 
the E-boxes close to SAE1 TSS site. 
 
While our studies on Myc role on SAE1 expres-
sion were in progress it has been reported the 
identification of genes vital to support Myc-
addicted tumors through a genome wide ge-
netic screen for Myc-synthetic lethal (MySL) 
shRNAs in human mammary epithelial cells [5]. 
The most significant candidates that have been 
isolated in this study are the SAE1 and SAE2 
genes whose products associate to form the 
heterodimer that is a critical component of the 
SUMO activating enzyme needed for SUMO con-
jugation to proteins [4]. The authors found that 
SAE was required for growth of Myc dependent 
tumors and that the low expression of SAE1/2 
in human breast cancers with high Myc expres-
sion levels correlates with longer survival of the 
patients. SAE depleted cells with high levels of 
Myc expression were found impaired in a cor-
rect mitotic spindle formation and consequently 
committed to apoptosis highlighting the crucial 
role of the SAE gene expression in Myc medi-
ated oncogenesis. 
 
Our study adds new insight in this context since 
we show here that Myc directly activates SAE1 
transcription, suggesting that Myc oncogenic 
activity which depends on SAE1 is ensured by 
Myc itself through direct binding and transcrip-
tional activation of SAE1 expression. Thus, re-
cruitment of Myc on SAE1 modulates its expres-
sion supporting Myc oncogenic program by acti-
Figure 3. A general schematic of SAE1/PUMA locus showing CTCF binding sites and identified Myc binding sites (E-
box). 
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vation of Sumoylation dependent Myc-switchers 
(SMS genes).  
 
Intriguing is the fact that the PUMA and SAE1 
are adjacent on the human chromosome 19 
and that their expression has been always 
found inversely correlated. While Myc cooper-
ates with PI3/AKT pathway to repress PUMA 
transcription, hyper activation of Myc activates 
SAE1 transcription. An extensive analysis of 
chromatin domains at the PUMA locus and sur-
rounding region including SAE1, has been re-
cently provided by the Espinosa’s laboratory 
[11, 12]. It has been identified a peculiar tran-
scriptional organization of the locus with the 
presence of the insulator protein CTCF (CCCTC-
binding factor) and the associated cohesin com-
plex at intragenic PUMA as well as at intergenic 
regions between PUMA and SAE1 (Figure 3). 
Since CTCF functions involve the formation of 
‘chromatin loops’ and these loops seems to be 
regulated in a signaling specific manner [13], it 
is possible that Myc binding might induce an 
intergenic gene looping between PUMA and 
SAE1 leading to the divergent Myc-mediated 
transcription control of SAE1 and PUMA loci. 
Further investigations will be necessary to vali-
date these speculative hypotheses. 
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